

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 5/10 // A61K 48/00</b>		A1	(11) International Publication Number: <b>WO 97/00326</b>
			(43) International Publication Date: <b>3 January 1997 (03.01.97)</b>
(21) International Application Number: <b>PCT/NL96/00244</b>		(74) Agent: SMULDERS, Th., A., H., J.; Vereenigde Octrooibureau, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).	
(22) International Filing Date: <b>14 June 1996 (14.06.96)</b>			
(30) Priority Data: 95201611.1 15 June 1995 (15.06.95) EP (34) Countries for which the regional or international application was filed: NL et al. 95201728.3 26 June 1995 (26.06.95) EP (34) Countries for which the regional or international application was filed: NL et al.		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIP0 patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): INTROGENE B.V. [NL/NL]; Lange Kleiweg 151, NL-2288 GJ Rijswijk (NL). RIJKSUNIVERSITEIT LEIDEN [NL/NL]; Stationsweg 46, NL-2312 AV Leiden (NL).		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): FALLAUX, Frits, Jacobus [NL/NL]; Peppelschans 77, NL-2352 BE Leiderdorp (NL). HOEBEN, Robert, Cornelis [NL/NL]; Gerbrandylaan 43, NL-2314 EX Leiden (NL). BOUT, Abraham [NL/NL]; Cuymansstraat 24, NL-2751 AR Moerkapelle (NL). VALERIO, Domenico [NL/NL]; Gerbrandylaan 12, NL-2314 EZ Leiden (NL). VAN DER EB, Alex, Jan [NL/NL]; Prinses Beatrixlaan 53, NL-2341 TW Oegstgeest (NL).			

(54) Title: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO BE USED IN GENE THERAPY

(57) Abstract

The invention provides improved methods and products based on adenoviral materials which can advantageously be used in for instance gene therapy. In one aspect an adenoviral vector is provided which has no overlap with a suitable packaging cell line which is another aspect of invention. This combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. In another aspect an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Further a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, which all have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system. Further a method of intracellular amplification is provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Title: Packaging systems for human recombinant adenovirus to be used in gene therapy.

The invention relates to the field of recombinant DNA technology, more in particular to the field of gene therapy. In particular the invention relates to gene therapy using materials derived from adenovirus, in 5 particular human recombinant adenovirus. It especially relates to novel virus derived vectors and novel packaging cell lines for vectors based on adenoviruses.

Gene therapy is a recently developed concept for which a wide range of applications can be and have been 10 envisaged.

In gene therapy a molecule carrying genetic information is introduced into some or all cells of a host, as a result of which the genetic information is added to the host in a functional format.

15 The genetic information added may be a gene or a derivative of a gene, such as a cDNA, which encodes a protein. In this case the functional format means that the protein can be expressed by the machinery of the host cell.

20 The genetic information can also be a sequence of nucleotides complementary to a sequence of nucleotides (be it DNA or RNA) present in the host cell. The functional format in this case is that the added DNA (nucleic acid) molecule or copies made thereof in situ are capable of 25 base pairing with the complementary sequence present in the host cell.

Applications include the treatment of genetic disorders by supplementing a protein or other substance which is, through said genetic disorder, not present or at 30 least present in insufficient amounts in the host, the treatment of tumors and (other) acquired diseases such as (auto)immune diseases or infections, etc.

As may be clear from the above, there are basically three different approaches in gene therapy, one directed towards compensating a deficiency present in a (mammalian) host; the second directed towards the removal or elimination of unwanted substances (organisms or cells) and the third towards application of a recombinant vaccine (tumors or foreign micro-organisms).

For the purpose of gene therapy, adenoviruses carrying deletions have been proposed as suitable vehicles.

10 Adenoviruses are non-enveloped DNA viruses. Gene-transfer vectors derived from adenoviruses (so-called adenoviral vectors) have a number of features that make them particularly useful for gene transfer for such purposes. Eg., the biology of the adenoviruses is characterized in detail,

15 the adenovirus is not associated with severe human pathology, the virus is extremely efficient in introducing its DNA into the host cell, the virus can infect a wide variety of cells and has a broad host-range, the virus can be produced in large quantities with relative ease, and the virus can be

20 rendered replication defective by deletions in the early-region 1 (E1) of the viral genome.

The adenovirus genome is a linear double-stranded DNA molecule of approximately 36000 base pairs with the 55-kDa terminal protein covalently bound to the 5' terminus of each strand. The Ad DNA contains identical Inverted Terminal Repeats (ITR) of about 100 base pairs with the exact length depending on the serotype. The viral origins of replication are located within the ITRs exactly at the genome ends. DNA synthesis occurs in two stages. First, the replication

25 proceeds by strand displacement, generating a daughter duplex molecule and a parental displaced strand. The displaced strand is single stranded and can form a so-called "panhandle" intermediate, which allows replication initiation and generation of a daughter duplex molecule. Alternatively,

30 replication may proceed from both ends of the genome simultaneously, obviating the requirement to form the

35

panhandle structure. The replication is summarized in Figure 14 adapted from (Lechner and Kelly, 1977).

During the productive infection cycle, the viral genes are expressed in two phases: the early phase, which 5 is the period upto viral DNA replication, and the late phase, which coincides with the initiation of viral DNA replication. During the early phase only the early gene products, encoded by regions E1, E2, E3 and E4, are expressed, which carry out a number of functions that 10 prepare the cell for synthesis of viral structural proteins (Berk, 1986). During the late phase the late viral gene products are expressed in addition to the early gene products and host cell DNA and protein synthesis are shut off. Consequently, the cell becomes dedicated to the 15 production of viral DNA and of viral structural proteins (Tooze, 1981).

The E1 region of adenovirus is the first region of adenovirus expressed after infection of the target cell. This region consists of two transcriptional units, the E1A 20 and E1B genes, which both are required for oncogenic transformation of primary (embryonal) rodent cultures. The main functions of the E1A gene products are:  
i) to induce quiescent cells to enter the cell cycle and resume cellular DNA synthesis, and  
25 ii) to transcriptionally activate the E1B gene and the other early regions (E2, E3, E4). Transfection of primary cells with the E1A gene alone can induce unlimited proliferation (immortalization), but does not result in complete transformation. However, expression of E1A in 30 most cases results in induction of programmed cell death (apoptosis), and only occasionally immortalization is obtained (Jochimsen et al., 1987). Co-expression of the E1B gene is required to prevent induction of apoptosis and for complete morphological transformation to occur. In 35 established immortal cell lines, high level expression of E1A can cause complete transformation in the absence of E1B (Roberts et al., 1985).

- The ElB encoded proteins assist ElA in redirecting the cellular functions to allow viral replication. The ElB 55 kD and E4 33kD proteins, which form a complex that is essentially localized in the nucleus, function in
- 5 inhibiting the synthesis of host proteins and in facilitating the expression of viral genes. Their main influence is to establish selective transport of viral mRNAs from the nucleus to the cytoplasm, concomittantly with the onset of the late phase of infection. The ElB 21
- 10 kD protein is important for correct temporal control of the productive infection cycle, thereby preventing premature death of the host cell before the virus life cycle has been completed. Mutant viruses incapable of expressing the ElB 21 kD gene-product exhibit a shortened
- 15 infection cycle that is accompanied by excessive degradation of host cell chromosomal DNA (*deg*-phenotype) and in an enhanced cytopathic effect (*cyt*-phenotype) (Telling et al., 1994). The *deg* and *cyt* phenotypes are suppressed when in addition the ElA gene is mutated,
- 20 indicating that these phenotypes are a function of ElA (White et al., 1988). Furthermore, the ElB 21 kDa protein slows down the rate by which ElA switches on the other viral genes. It is not yet known through which mechanisms ElB 21 kD quenches these ElA dependent functions.
- 25 Vectors derived from human adenoviruses, in which at least the El region has been deleted and replaced by a gene of interest, have been used extensively for gene therapy experiments in the pre-clinical and clinical phase.
- 30 As stated before all adenovirus vectors currently used in gene therapy have a deletion in the El region, where novel genetic information can be introduced. The El deletion renders the recombinant virus replication defective (Stratford-Perricaudet and Perricaudet, 1991).
- 35 We have demonstrated that recombinant adenoviruses are able to efficiently transfer recombinant genes to the rat liver and airway epithelium of rhesus monkeys (Bout et

al., 1994b; Bout et al., 1994a). In addition, we (Vincent et al., 1996a; Vincent et al., 1996b) and others (see e.g. Haddada et al., 1993) have observed a very efficient *in vivo* adenovirus mediated gene transfer to a variety of tumor cells *in vitro* and to solid tumors in animals models (lung tumors, glioma) and human xenografts in immunodeficient mice (lung) *in vivo* (reviewed by Blaese et al., 1995).

In contrast to for instance retroviruses, adenoviruses a) do not integrate into the host cell genome; b) are able to infect non-dividing cells and c) are able to efficiently transfer recombinant genes *in vivo* (Brody and Crystal, 1994). Those features make adenoviruses attractive candidates for *in vivo* gene transfer of, for instance, suicide or cytokine genes into tumor cells.

However, a problem associated with current recombinant adenovirus technology is the possibility of unwanted generation of replication competent adenovirus (RCA) during the production of recombinant adenovirus (Lochmüller et al., 1994; Imler et al., 1996). This is caused by homologous recombination between overlapping sequences from the recombinant vector and the adenovirus constructs present in the complementing cell line, such as the 293 cells (Graham et al., 1977). RCA in batches to be used in clinical trials is unwanted because RCA i) will replicate in an uncontrolled fashion; ii) can complement replication defective recombinant adenovirus, causing uncontrolled multiplication of the recombinant adenovirus and iii) batches containing RCA induce significant tissue damage and hence strong pathological side effects (Lochmüller et al., 1994). Therefore, batches to be used in clinical trials should be proven free of RCA (Ostrove, 1994). In one aspect of the invention this problem in virus production is solved in that we have developed packaging cells that have no overlapping sequences with a new basic vector and thus are suited for safe large scale

production of recombinant adenoviruses one of the additional problems associated with the use of recombinant adenovirus vectors is the host-defence reaction against treatment with adenovirus.

5 Briefly, recombinant adenoviruses are deleted for the E1 region (see above). The adenovirus E1 products trigger the transcription of the other early genes (E2, E3, E4), which consequently activate expression of the late virus genes. Therefore, it was generally thought that E1 deleted  
10 vectors would not express any other adenovirus genes. However, recently it has been demonstrated that some cell types are able to express adenovirus genes in the absence of E1 sequences. This indicates, that some cell types possess the machinery to drive transcription of adenovirus  
15 genes. In particular, it was demonstrated that such cells synthesize E2A and late adenovirus proteins.

In a gene therapy setting, this means that transfer of the therapeutic recombinant gene to somatic cells not only results in expression of the therapeutic protein but  
20 may also result in the synthesis of viral proteins. Cells that express adenoviral proteins are recognized and killed by Cytotoxic T Lymphocytes, which thus a) eradicates the transduced cells and b) causes inflammations (Bout et al., 1994a; Engelhardt et al., 1993; Simon et al., 1993). As  
25 this adverse reaction is hampering gene therapy, several solutions to this problem have been suggested, such as a) using immunosuppressive agents after treatment; b)  
retainment of the adenovirus E3 region in the recombinant vector (see patent application EP 95202213) and c) and  
30 using ts mutants of human adenovirus, which have a point mutation in the E2A region (patent WO/28938).

However, these strategies to circumvent the immune response have their limitations.

The use of ts mutant recombinant adenovirus  
35 diminishes the immune response to some extent, but was less effective in preventing pathological responses in the lungs (Engelhardt et al., 1994a).

The E2A protein may induce an immune response by itself and it plays a pivotal role in the switch to the synthesis of late adenovirus proteins. Therefore, it is attractive to make recombinant adenoviruses which are 5 mutated in the E2 region, rendering it temperature sensitive (ts), as has been claimed in patent application WO/28938.

A major drawback of this system is the fact that, although the E2 protein is unstable at the non-permissive 10 temperature, the immunogenic protein is still being synthesized. In addition, it is to be expected that the unstable protein does activate late gene expression, albeit to a low extent. ts125 mutant recombinant adenoviruses have been tested, and prolonged recombinant 15 gene expression was reported (Yang et al., 1994b; Engelhardt et al., 1994a; Engelhardt et al., 1994b; Yang et al., 1995). However, pathology in the lungs of cotton rats was still high (Engelhardt et al., 1994a), indicating that the use of ts mutants results in only a partial 20 improvement in recombinant adenovirus technology. Others (Fang et al., 1996) did not observe prolonged gene expression in mice and dogs using ts125 recombinant adenovirus. An additional difficulty associated with the 25 use of ts125 mutant adenoviruses is that a high frequency of reversion is observed. These revertants are either real revertants or the result of second site mutations (Kruijer et al., 1983; Nicolas et al., 1981). Both types of revertants have an E2A protein that functions at normal temperature and have therefore similar toxicity as the 30 wild-type virus.

In another aspect of the present invention we therefore delete E2A coding sequences from the recombinant adenovirus genome and transfet these E2A sequences into the (packaging) cell lines containing E1 sequences to complement recombinant adenovirus vectors. 35

Major hurdles in this approach are a) that E2A should be expressed to very high levels and b) that E2A protein is very toxic to cells.

The current invention in yet another aspect therefore discloses use of the ts125 mutant E2A gene, which produces a protein that is not able to bind DNA sequences at the non permissive temperature. High levels of this protein may be maintained in the cells (because it is not toxic at this temperature) until the switch to the permissive temperature is made. This can be combined with placing the mutant E2A gene under the direction of an inducible promoter, such as for instance tet, methallothionein, steroid inducible promoter, retinoic acid  $\beta$ -receptor or other inducible systems. However in yet another aspect of the invention, the use of an inducible promoter to control the moment of production of toxic wild-type E2A is disclosed.

Two salient additional advantages of E2A-deleted recombinant adenovirus are the increased capacity to harbor heterologous sequences and the permanent selection for cells that express the mutant E2A. This second advantage relates to the high frequency of reversion of ts125 mutation: when reversion occurs in a cell line harboring ts125 E2A, this will be lethal to the cell. Therefore, there is a permanent selection for those cells that express the ts125 mutant E2A protein. In addition, as we in one aspect of the invention generate E2A-deleted recombinant adenovirus, we will not have the problem of reversion in our adenoviruses.

In yet another aspect of the invention as a further improvement the use of non-human cell lines as packaging cell lines is disclosed.

For GMP production of clinical batches of recombinant viruses it is desirable to use a cell line that has been used widely for production of other biotechnology products. Most of the latter cell lines are from monkey origin, which have been used to produce e.g. vaccines.

These cells can not be used directly for the production of recombinant human adenovirus, as human adenovirus can not or only to low levels replicate in cells of monkey origin. A block in the switch of early to late phase of adenovirus 5 lytic cycle is underlying defective replication. However, host range mutations in the human adenovirus genome are described (hr400 - 404) which allow replication of human viruses in monkey cells. These mutations reside in the gene encoding E2A protein (Klessig and Grodzicker, 1979; 10 Klessig et al., 1984; Rice and Klessig, 1985)(Klessig et al., 1984). Moreover, mutant viruses have been described that harbor both the hr and temperature-sensitive ts125 phenotype (Brough et al., 1985; Rice and Klessig, 1985).

We therefore generate packaging cell lines of monkey 15 origin (e.g. VERO, CV1) that harbor:

- a. E1 sequences, to allow replication of E1/E2 defective adenoviruses, and
- b. E2A sequences, containing the hr mutation and the ts 125 mutation, named ts400 (Brough et al., 1985; Rice 20 and Klessig, 1985) to prevent cell death by E2A overexpression, and/or
- c. E2A sequences, just containing the hr mutation, under the control of an inducible promoter, and/or
- d. E2A sequences, containing the hr mutation and the ts 25 125 mutation (ts400), under the control of an inducible promoter

Furthermore we disclose the construction of novel and improved combinations of (novel and improved) packaging 30 cell lines and (novel and improved) recombinant adenovirus vectors. We provide:

1. a novel packaging cell line derived from diploid human embryonic retinoblasts (HER) that harbors nt. 80 - 5788 of the Ad5 genome. This cell line, named 911, deposited under no 95062101 at the ECACC, has many characteristics that make it superior to the commonly 35 used 293 cells (Fallaux et al., 1996).

2. novel packaging cell lines that express just ElA genes and not ElB genes.

Established cell lines (and not human diploid cells of which 293 and 911 cells are derived) are able to express ElA to high levels without undergoing apoptotic cell death, as occurs in human diploid cells that express ElA in the absence of ElB.

Such cell lines are able to trans-complement ElB-defective recombinant adenoviruses, because viruses mutated for ElB 21 kD protein are able to complete viral replication even faster than wild-type adenoviruses (Telling et al., 1994). The constructs are described in detail below, and graphically represented in Figures 1-5. The constructs are transfected into the different established cell lines and are selected for high expression of ElA. This is done by operatively linking a selectable marker gene (e.g. NEO gene) directly to the ElB promoter. The ElB promoter is transcriptionally activated by the ElA gene product and therefore resistance to the selective agent (e.g. G418 in the case NEO is used as the selection marker) results in direct selection for desired expression of the ElA gene

3. Packaging constructs that are mutated or deleted for ElB 21 kD, but just express the 55 kD protein.
4. Packaging constructs to be used for generation of complementing packaging cell lines from diploid cells (not exclusively of human origin) without the need of selection with marker genes. These cells are immortalized by expression of ElA. However, in this particular case expression of ElB is essential to prevent apoptosis induced by ElA proteins. Selection of El expressing cells is achieved by selection for focus formation (immortalization), as described for 293 cells (Graham et al., 1977) and 911 cells (Fallaux et al., 1996), that are El-transformed

human embryonic kidney (HEK) cells and human embryonic retinoblasts (HER), respectively.

5. After transfection of HER cells with construct pIG.E1B (Fig. 4), seven independent cell lines could be established. These cell lines were designated PER.C1, PER.C3, PER.C4, PER.C5, PER.C6, PER.C8 and PER.C9. PER denotes PGK-E1-Retinoblasts. These cell lines express E1A and E1B proteins, are stable (e.g. PER.C6 for more than 57 passages) and complement E1 defective adenovirus vectors. Yields of recombinant adenovirus obtained on PER cells are a little higher than obtained on 293 cells. One of these cell lines (PER.C6) has been deposited at the ECACC under number 96022940.
10. 6. New adenovirus vectors with extended E1 deletions (deletion nt. 459 - 3510). Those viral vectors lack sequences homologous to E1 sequences in said packaging cell lines. These adenoviral vectors contain pIX promoter sequences and the pIX gene, as pIX (from its natural promoter sequences) can only be expressed from the vector and not by packaging cells (Matsui et al., 1986, Hoeben and Fallaux, pers.comm.; Imier et al., 1996).
15. 7. E2A expressing packaging cell lines preferably based on either E1A expressing established cell lines or E1A - E1B expressing diploid cells (see under 2 - 4). E2A expression is either under the control of an inducible promoter or the E2A ts125 mutant is driven by either an inducible or a constitutive promoter.
20. 8. Recombinant adenovirus vectors as described before (see 6) but carrying an additional deletion of E2A sequences.
25. 9. Adenovirus packaging cells from monkey origin that are able to trans-complement E1-defective recombinant adenoviruses. They are preferably co-transfected with pIG.E1AE1B and pIG.NEO, and selected for NEO resistance. Such cells expressing E1A and E1B are able

- to transcomplement E1 defective recombinant human adenoviruses, but will do so inefficiently because of a block of the synthesis of late adenovirus proteins in cells of monkey origin (Klessig and Grodzicker, 1979). To overcome this problem, we generate recombinant adenoviruses that harbor a host-range mutation in the E2A gene, allowing human adenoviruses to replicate in monkey cells. Such viruses are generated as described in Figure 12, except DNA from a hr-mutant is used for homologous recombination.
10. Adenovirus packaging cells from monkey origin as described under 9, except that they will also be co-transfected with E2A sequences harboring the hr mutation. This allows replication of human adenoviruses lacking E1 and E2A (see under 8). E2A in these cell lines is either under the control of an inducible promoter or the tsE2A mutant is used. In the latter case, the E2A gene will thus carry both the ts mutation and the hr mutation (derived from ts400). Replication competent human adenoviruses have been described that harbor both mutations (Brough et al., 1985; Rice and Klessig, 1985).

A further aspect of the invention provides otherwise improved adenovirus vectors, as well as novel strategies for generation and application of such vectors and a method for the intracellular amplification of linear DNA fragments in mammalian cells.

The so-called "minimal" adenovirus vectors according to the present invention retain at least a portion of the viral genome that is required for encapsidation of the genome into virus particles (the encapsidation signal), as well as at least one copy of at least a functional part or a derivative of the Inverted Terminal Repeat (ITR), that is DNA sequences derived from the termini of the linear adenovirus genome. The vectors according to the present invention will also contain a transgene linked to a

promoter sequence to govern expression of the transgene. Packaging of the so-called minimal adenovirus vector can be achieved by co-infection with a helper virus or, alternatively, with a packaging deficient replicating helper system as described below.

Adenovirus-derived DNA fragments that can replicate in suitable cell lines and that may serve as a packaging deficient replicating helper system are generated as follows. These DNA fragments retain at least a portion of the transcribed region of the "late" transcription unit of the adenovirus genome and carry deletions in at least a portion of the E1 region and deletions in at least a portion of the encapsidation signal. In addition, these DNA fragments contain at least one copy of an inverted terminal repeat (ITR). At one terminus of the transfected DNA molecule an ITR is located. The other end may contain an ITR, or alternatively, a DNA sequence that is complementary to a portion of the same strand of the DNA molecule other than the ITR. If, in the latter case, the two complementary sequences anneal, the free 3'-hydroxyl group of the 3' terminal nucleotide of the hairpin-structure can serve as a primer for DNA synthesis by cellular and/or adenovirus-encoded DNA polymerases, resulting in conversion into a double-stranded form of at least a portion of the DNA molecule. Further replication initiating at the ITR will result in a linear double-stranded DNA molecule, that is flanked by two ITR's, and is larger than the original transfected DNA molecule (see Fig. 13). This molecule can replicate itself in the transfected cell by virtue of the adenovirus proteins encoded by the DNA molecule and the adenoviral and cellular proteins encoded by genes in the host-cell genome. This DNA molecule can not be encapsidated due to its large size (greater than 39000 base pairs) or due to the absence of a functional encapsidation signal. This DNA molecule is intended to serve as a helper for the

production of defective adenovirus vectors in suitable cell lines.

The invention also comprises a method for the amplification of linear DNA fragments of variable size in suitable mammalian cells. These DNA fragments contain at least one copy of the ITR at one of the termini of the fragment. The other end may contain an ITR, or alternatively, a DNA sequence that is complementary to a portion of the same strand of the DNA molecule other than the ITR. If, in the latter case, the two complementary sequences anneal, the free 3'-hydroxyl group of the 3' terminal nucleotide of the hairpin-structure can serve as a primer for DNA synthesis by cellular and/or adenovirus-encoded DNA polymerases, resulting in conversion of the displaced stand into a double stranded form of at least a portion of the DNA molecule. Further replication initiating at the ITR will result in a linear double-stranded DNA molecule, that is flanked by two ITR's, which is larger than the original transfected DNA molecule. A DNA molecule that contains ITR sequences at both ends can replicate itself in transfected cells by virtue of the presence of at least the adenovirus E2 proteins (viz. the DNA-binding protein (DBP), the adenovirus DNA polymerase (Ad-pol), and the preterminal protein (pTP). The required proteins may be expressed from adenovirus genes on the DNA molecule itself, from adenovirus E2 genes integrated in the host-cell genome, or from a replicating helper fragment as described above.

Several groups have shown that the presence of ITR sequences at the end of DNA molecules are sufficient to generate adenovirus minichromosomes that can replicate, if the adenovirus-proteins required for replication are provided in trans e.g. by infection with a helpervirus (Hu et al., 1992); (Wang and Pearson, 1985); (Hay et al., 1984). Hu et al., (1992) observed the presence and replication of symmetrical adenovirus minichromosome-dimers after transfection of plasmids containing a single

ITR. The authors were able to demonstrate that these dimeric minichromosomes arise after tail-to-tail ligation of the single ITR DNA molecules. In DNA extracted from defective adenovirus type 2 particles, dimeric molecules of various sizes have also been observed using electron-microscopy (Daniell, 1976). It was suggested that the incomplete genomes were formed by illegitimate recombination between different molecules and that variations in the position of the sequence at which the illegitimate base pairing occurred were responsible for the heterogeneous nature of the incomplete genomes. Based on this mechanism it was speculated that, in theory, defective molecules with a total length of up to two times the normal genome could be generated. Such molecules could contain duplicated sequences from either end of the genome. However, no DNA molecules larger than the full-length virus were found packaged in the defective particles (Daniell, 1976). This can be explained by the size-limitations that apply to the packaging. In addition, it was observed that in the virus particles DNA-molecules with a duplicated left-end predominated over those containing the right-end terminus (Daniell, 1976). This is fully explained by the presence of the encapsidation signal near that left-end of the genome (Gräble and Hearing, 1990; Gräble and Hearing, 1992; Hearing et al., 1987).

The major problems associated with the current adenovirus-derived vectors are:

- A) The strong immunogenicity of the virus particle
- B) The expression of adenovirus genes that reside in the adenoviral vectors, resulting in a Cytotoxic T-cell response against the transduced cells.
- C) The low amount of heterologous sequences that can be accommodated in the current vectors (Up to maximally approx. 8000 bp. of heterologous DNA).

- Ad A) The strong immunogenicity of the adenovirus particle results in an immunological response of the host, even after a single administration of the adenoviral vector. As a result of the development of neutralizing antibodies, a subsequent administration of the virus will be less effective or even completely ineffective. However, a prolonged or persistent expression of the transferred genes will reduce the number of administrations required and may bypass the problem.
- Ad B) Experiments performed by Wilson and collaborators have demonstrated that after adenovirus-mediated gene transfer into immunocompetent animals, the expression of the transgene gradually decreases and disappears approximately 2 - 4 weeks post-infection (Yang et al., 1994a; Yang et al., 1994b). This is caused by the development of a Cytotoxic T-Cell (CTL) response against the transduced cells. The CTLs were directed against adenovirus proteins expressed by the viral vectors. In the transduced cells synthesis of the adenovirus DNA-binding protein (the E2A-gene product), penton and fiber proteins (late-gene products) could be established. These adenovirus proteins, encoded by the viral vector, were expressed despite deletion of the E1 region. This demonstrates that deletion of the E1 region is not sufficient to completely prevent expression of the viral genes (Engelhardt et al., 1994a).

Ad C) Studies by Graham and collaborators have demonstrated that adenoviruses are capable of encapsidating DNA of up to 105% of the normal genome size (Bett et al., 1993). Larger genomes tend to be instable resulting in loss of DNA sequences during propagation of the virus. Combining deletions in the E1 and E3 regions of the viral genomes increases the maximum size of the foreign that can be encapsidated to approx. 8.3 kb. In addition, some sequences of the E4 region appear to be dispensable for virus growth (adding another 1.8 kb to the maximum encapsidation capacity). Also the E2A region can

be deleted from the vector, when the E2A gene product is provided in trans in the encapsidation cell line, adding another 1.6 kb. It is, however, unlikely that the maximum capacity of foreign DNA can be significantly increased 5 further than 12 kb.

We developed a new strategy for the generation and production of helperfree-stocks of recombinant adenovirus vectors that can accomodate up to 38 kb of foreign DNA. Only two functional ITR sequences, and sequences that can 10 function as an encapsidation signal need to be part of the vector genome. Such vectors are called minimal adenovectors. The helper functions for the minimal adenovectors are provided in trans by encapsidation defective-replication competent DNA molecules that contain 15 all the viral genes encoding the required gene products, with the exception of those genes that are present in the host-cell genome, or genes that reside in the vector genome.

The applications of the disclosed inventions are 20 outlined below and will be illustrated in the experimental part, which is only intended for said purpose, and should not be used to reduce the scope of the present invention as understood by the person skilled in the art.

25 Use of the IG packaging constructs Diploid cells.

The constructs, in particular pIG.E1A.E1B, will be used to transfet diploid human cells, such as Human Embryonic Retinoblasts (HER), Human Embryonic Kidney cells 30 (HEK), and Human Embryonic Lung cells (HEL). Transfected cells will be selected for transformed phenotype (focus formation) and tested for their ability to support propagation of El-deleted recombinant adenovirus, such as IG.Ad.MLPI.TK. Such cell lines will be used for the 35 generation and (large-scale) production of El-deleted recombinant adenoviruses. Such cells, infected with recombinant adenovirus are also intended to be used

in vivo as a local producer of recombinant adenovirus, e.g. for the treatment of solid tumors.

911 cells are used for the titration, generation and production of recombinant adenovirus vectors (Fallaux et al., 1996).

HER cells transfected with pIG.E1A.E1B has resulted in 7 independent clones (called PER cells). These clones are used for the production of E1 deleted (including non-overlapping adenovirus vectors) or E1 defective recombinant adenovirus vectors and provide the basis for introduction of e.g. E2B or E2A constructs (e.g. ts125E2A, see below), E4 etc., that will allow propagation of adenovirus vectors that have mutations in e.g. E2A or E4.

In addition, diploid cells of other species that are permissive for human adenovirus, such as the cotton rat (*Sigmodon hispidus*) (Pacini et al., 1984), Syrian hamster (Morin et al., 1987) or chimpanzee (Levrero et al., 1991), will be immortalized with these constructs. Such cells, infected with recombinant adenovirus, are also intended to be used in vivo for the local production of recombinant adenovirus, e.g. for the treatment of solid tumors.

#### Established cells.

The constructs, in particular pIG.E1A.NEO, can be used to transfect established cells, e.g. A549 (human bronchial carcinoma), KB (oral carcinoma), MRC-5 (human diploid lung cell line) or GLC cell lines (small cell lung cancer) (de Leij et al., 1985; Postmus et al., 1988) and selected for NEO resistance. Individual colonies of resistant cells are isolated and tested for their capacity to support propagation of E1-deleted recombinant adenovirus, such as IG.Ad.MLPI.TK. When propagation of E1 deleted viruses on E1A containing cells is possible, such cells can be used for the generation and production of E1-deleted recombinant adenovirus. They are also be used

for the propagation of E1A deleted/E1B retained recombinant adenovirus.

Established cells can also be co-transfected with pIG.E1A.E1B and pIG.NEO (or another NEO containing expression vector). Clones resistant to G418 are tested for their ability to support propagation of E1 deleted recombinant adenovirus, such as IG.Ad.MLPI.TK and used for the generation and production of E1 deleted recombinant adenovirus and will be applied *in vivo* for local production of recombinant virus, as described for the diploid cells (see above).

All cell lines, including transformed diploid cell lines or NEO-resistant established lines, can be used as the basis for the generation of 'next generation' packaging cells lines, that support propagation of E1-defective recombinant adenoviruses, that also carry deletions in other genes, such as E2A and E4. Moreover, they will provide the basis for the generation of minimal adenovirus vectors as disclosed herein.

20

#### E2 expressing cell lines

Packaging cells expressing E2A sequences are and will be used for the generation and (large scale) production of E2A-deleted recombinant adenovirus.

The newly generated human adenovirus packaging cell lines or cell lines derived from species permissive for human adenovirus (E2A or ts125E2A; E1A - E2A; E1A + E1B - E2A; E1A - E2A/ts125; E1A + E1B - E2A/ts125) or non-permissive cell lines such as monkey cells (hrE2A or hr + ts125E2A; E1A - hrE2A; E1A - E1B - hrE2A; E1A - hrE2A/ts125; E1A - E1B + hrE2A/ts125) are and will be used for the generation and (large scale) production of E2A deleted recombinant adenovirus vectors. In addition, they will be applied *in vivo* for local production of recombinant virus, as described for the diploid cells (see above).

Novel adenovirus vectors.

The newly developed adenovirus vectors harboring an E1 deletion of nt. 459-3510 will be used for gene transfer purposes. These vectors are also the basis for the development of further deleted adenovirus vectors that are mutated for e.g. E2A, E2B or E4. Such vectors will be generated e.g. on the newly developed packaging cell lines described above (see 1-3).

10

Minimal adenovirus packaging system

We disclose adenovirus packaging constructs (to be used for the packaging of minimal adenovirus vectors) may have the following characteristics:

- a. the packaging construct replicates
- b. the packaging construct can not be packaged because the packaging signal is deleted
- c. the packaging construct contains an internal hairpin-forming sequence (see section 'Experimental: suggested hairpin' see Fig. 15)
- d. because of the internal hairpin structure, the packaging construct is duplicated, that is the DNA of the packaging construct becomes twice as long as it was before transfection into the packaging cell (in our sample it duplicates from 35 kb to 70 kb). This duplication also prevents packaging. Note that this duplicated DNA molecule has ITR's at both termini (see e.g. Fig. 13)
- e. this duplicated packaging molecule is able to replicate like a 'normal adenovirus' DNA molecule
- f. the duplication of the genome is a prerequisite for the production of sufficient levels of adenovirus proteins, required to package the minimal adenovirus vector

35

g. the packaging construct has no overlapping sequences with the minimal vector or cellular sequences that may lead to generation of RCA by homologous recombination.

5

This packaging system will be used to produce minimal adenovirus vectors. The advantages of minimal adenovirus vectors e.g. for gene therapy or vaccination purposes, are well known (accommodation of up to 38 kb; gutting of all 10 potentially toxic and immunogenic adenovirus genes).

Adenovirus vectors containing mutations in essential genes (including minimal adenovirus vectors) can also be propagated using this system.

15 Use of intracellular E2 expressing vectors.

Minimal adenovirus vectors are generated using the helper functions provided in trans by packaging-deficient replicating helper molecules. The adenovirus-derived ITR 20 sequences serve as origins of DNA replication in the presence of at least the E2-gene products. When the E2 gene products are expressed from genes in the vector genome (N.B. the gene(s) must be driven by an El-independent promoter), the vector genome can replicate in 25 the target cells. This will allow an significantly increased number of template molecules in the target cells, and, as a result an increased expression of the genes of interest encoded by the vector. This is of particular interest for approaches of gene therapy in 30 cancer.

Applications of intracellular amplification of linear DNA fragments.

35 A similar approach could also be taken if amplification of linear DNA fragments is desired. DNA fragments of known or unknown sequence could be amplified

in cells containing the E2-gene products if at least one ITR sequence is located near or at its terminus. There are no apparent constraints on the size of the fragment. Even fragments much larger than the adenovirus genome (36 kb) should be amplified using this approach. It is thus possible to clone large fragments in mammalian cells without either shuttling the fragment into bacteria (such as *E.coli*) or use the polymerase chain reaction (P.C.R.). At the end stage of an productive adenovirus infection a single cell can contain over 100,000 copies of the viral genome. In the optimal situation, the linear DNA fragments can be amplified to similar levels. Thus, one should be able to extract more than 5 µg of DNA fragment per 10 million cells (for a 35-kbp fragment). This system can be used to express heterologous proteins equivalent to the Simian Virus 40-based COS-cell system; for research or for therapeutic purposes. In addition, the system can be used to identify genes in large fragments of DNA. Random DNA fragments may be amplified (after addition of ITRs) and expressed during intracellular amplification. Election or, selection of those cells with the desired phenotype can be used to enrich the fragment of interest and to isolate the gene.

25 EXPERIMENTAL

Generation of cell lines able to transcomplement El defective recombinant adenovirus vectors.

1. 911 cell line

30 We have generated a cell line that harbors El sequences of adenovirus type 5, able to trans-complement El deleted recombinant adenovirus (Fallaux et al., 1996).

This cell line was obtained by transfection of human diploid human embryonic retinoblasts (HER) with pAd5XhoIC, 35 that contains nt. 80 - 5788 of Ad5; one of the resulting transformants was designated 911. This cell line has been shown to be very useful in the propagation of El defective

recombinant adenovirus. It was found to be superior to the 293 cells. Unlike 293 cells, 911 cells lack a fully transformed phenotype, which most likely is the cause of performing better as adenovirus packaging line:

5 plaque assays can be performed faster (4 - 5 days instead of 8-14 days on 293)

monolayers of 911 cells survive better under agar overlay as required for plaque assays

higher amplification of El-deleted vectors

10

In addition, unlike 293 cells that were transfected with sheared adenoviral DNA, 911 cells were transfected using a defined construct. Transfection efficiencies of 911 cells are comparable to those of 293.

15

New packaging constructs.

Source of adenovirus sequences.

Adenovirus sequences are derived either from 20 pAd5.SalB, containing nt. 80 - 9460 of human adenovirus type 5 (Bernards et al., 1983) or from wild-type Ad5 DNA.

pAd5.SalB was digested with SalI and XbaI and the large fragment was religated and this new clone was named pAd5.X/S.

25

The pTN construct (constructed by Dr. R. Vogels, IntroGene, The Netherlands) was used as a source for the human PGK promoter and the NEO gene.

Human PGK promoter and NEO<sup>R</sup> gene.

30

Transcription of ElA sequences in the new packaging constructs is driven by the human PGK promoter (Michelson et al., 1983; Singer-Sam et al., 1984), derived from plasmid pTN (gift of R. Vogels), which uses pUC119 (Vieira and Messing, 1987) as a backbone. This plasmid was also used as a source for NEO gene fused to the Hepatitis B Virus (HBV) poly-adenylation signal.

## Fusion of PGK promoter to El genes (Fig. 1)

In order to replace the El sequences of Ad5 (ITR, origin of replication and packaging signal) by heterologous sequences we have amplified El sequences (nt. 459 to nt. 960) of Ad5 by PCR, using primers Ea1 and Ea2 (see Table I). The resulting PCR product was digested with ClaI and ligated into Bluescript (Stratagene), predigested with ClaI and EcoRV, resulting in construct PBS.PCRI.

Vector pTN was digested with restriction enzymes EcoRI (partially) and ScaI, and the DNA fragment containing the PGK promoter sequences was ligated into PBS.PCRI digested with ScaI and EcoRI. The resulting construct PBS.PGK.PCRI contains the human PGK promoter operatively linked to Ad5 El sequences from nt. 459 to nt. 916.

## Construction of pIG.E1A.E1B.X (Fig. 2)

20

pIG.E1A.E1B.X was made by replacing the ScaI-BspEI fragment of pAT-X/S by the corresponding fragment from PBS.PGK.PCRI (containing the PGK promoter linked to E1A sequences).

25

pIG.E1A.E1B.X contains the E1A and E1B coding sequences under the direction of the PGK promoter.

As Ad5 sequences from nt. 459 to nt. 5788 are present in this construct, also pIX protein of adenovirus is encoded by this plasmid.

30

## Construction of pIG.E1A.NEO (Fig. 3)

35

In order to introduce the complete E1B promoter and to fuse this promoter in such a way that the AUG codon of E1B 21 kD exactly functions as the AUG codon of NEO<sup>R</sup>, we amplified the E1B promoter using primers Ea3 and Ep2, where primer Ep2 introduces an NcoI site in the PCR

fragment. The resulting PCR fragment, named PCRII, was digested with HpaI and NcoI and ligated into pAT-X/S, which was predigested with HpaI and with NcoI. The resulting plasmid was designated pAT-X/S-PCR2. The NcoI - 5 StuI fragment of pTN, containing the NEO gene and part of the Hepatitis B Virus (HBV) polyadenylation signal, was cloned into pAT-X/S-PCR2 (digested with NcoI and NruI). The resulting construct: pAT-PCR2-NEO. The polyadenylation signal was completed by replacing the SacI-SalI fragment of pAT-PCR2-NEO by the corresponding fragment of pTN (resulting in pAT-PCR2-NEO.p(A)). The SacI-XbaI of pAT-PCR2-NEO.p(A) was replaced by the corresponding fragment of pIG.E1A.E1B-X, containing the PGK promoter linked to E1A genes.

10 15 The resulting construct was named pIG.E1A.NEC, and thus contains Ad5 E1 sequences (nt. 459 to nt 1713) under the control of the human PGK promoter.

20 Construction of pIG.E1A.E1B (Fig. 4)

25 pIG.E1A.E1B was made by amplifying the sequences encoding the N-terminal amino acids of E1B 55kd using primers Ebl and Eb2 (introduces a XhoI site). The resulting PCR fragment was digested with BglII and cloned into BglII/NruI of pAT-X/S, thereby obtaining pAT-PCR3.

pIG.E1A.E1B was constructed by introducing the HBV poly(A) sequences of pIG.E1A.NEO downstream of E1B sequences of pAT-PCR3 by exchange of XbaI - SalI fragment of pIG.E1A.NEO and the XbaI XhoI fragment of pAT-PCR3.

30 pIG.E1A.E1B contains nt. 459 to nt. 3510 of Ad5, that encode the E1A and E1B proteins. The E1B sequences are terminated at the splice acceptor at nt. 3511. No pIX sequences are present in this construct.

**Construction of pIG.NEO (Fig. 5)**

PIG.NEO was generated by cloning the HpaI - ScaI fragment of pIG.E1A.NEO, containing the NEO gene under the control of the Ad.5 E1B promoter, into pBS digested with EcoRV and ScaI.

This construct is of use when established cells are transfected with E1A.E1B constructs and NEO selection is required. Because NEO expression is directed by the E1B promoter, NEO resistant cells are expected to co-express E1A, which also is advantageous for maintaining high levels of expression of E1A during long-term culture of the cells.

**15 Testing of constructs.**

The integrity of the constructs pIG.E1A.NEO, pIG.E1A.E1B.X and pIG.E1A.E1B was assessed by restriction enzyme mapping; furthermore, parts of the constructs that were obtained by PCR analysis were confirmed by sequence analysis. No changes in the nucleotide sequence were found.

The constructs were transfected into primary BRK (Baby Rat Kidney) cells and tested for their ability to immortalize (pIG.E1A.NEO) or fully transform (pAd5.XhoIC, pIG.E1A.E1B.X and pIG.E1A.E1B) these cells.

Kidneys of 6-day old WAG-Rij rats were isolated, homogenized and trypsinized. Subconfluent dishes (diameter 5 cm) of the BRK cell cultures were transfected with 1 or 25 5 µg of pIG.NEO, pIG.E1A.NEO, pIG.E1A.E1B, pIG.E1A.E1B.X, pAd5XhoIC, or with pIG.E1A.NEO together with PDC26 (Van der Elsen et al., 1983), carrying the Ad5.E1B gene under control of the SV40 early promoter. Three weeks post-transfection, when foci were visible, the dishes were 30 fixed, Giemsa stained and the foci counted.

An overview of the generated adenovirus packaging constructs, and their ability to transform BRK, is

presented in Fig. 6. The results indicate that the constructs pIG.E1A.E1B and pIG.E1A.E1B.X are able to transform BRK cells in a dose-dependent manner. The efficiency of transformation is similar for both 5 constructs and is comparable to what was found with the construct that was used to make 911 cells, namely pAd5.XhoIC.

As expected, pIG.E1A.NEO was hardly able to immortalize BRK. However, co-transfection of an E1B 10 expression construct (PDC26) did result in a significant increase of the number of transformants (18 versus 1), indicating that E1A encoded by pIG.E1A.NEO is functional.

We conclude therefore, that the newly generated 15 packaging constructs are suited for the generation of new adenovirus packaging lines.

#### Generation of cell lines with new packaging constructs Cell lines and cell culture

20 Human A549 bronchial carcinoma cells (Shapiro et al., 1978), human embryonic retinoblasts (HER), Ad5-E1-transformed human embryonic kidney (HEK) cells (293; Graham et al., 1977) cells and Ad5-transformed HER cells (911; Fallaux et al., 1996)) and PER cells were grown in 25 Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) and antibiotics in a 5% CO<sub>2</sub> atmosphere at 37°C. Cell culture media, reagents and sera were purchased from Gibco Laboratories (Grand Island, NY). Culture plastics were purchased from Greiner (Nürtingen, 30 Germany) and Corning (Corning, NY).

#### Viruses and virus techniques

##### The construction of adenoviral vectors

35 IG.Ad.MLP.nls.lacZ, IG.Ad.MLP.luc, IG.Ad.MLP.TK and IG.Ad.CMV.TK is described in detail in patent application EP 95202213.

(Zantema et al., 1985). The second antibody was a horseradish peroxidase-labeled goat anti-mouse antibody (Promega). Signals were visualized by enhanced chemoluminescence (Amersham Corp, UK).

5

#### Southern blot analysis

High molecular weight DNA was isolated and 10 µg was digested to completion and fractionated on a 0.7% agarose 10 gel. Southern blot transfer to Hybond N+ (Amersham, UK) was performed with a 0.4 M NaOH, 0.6 M NaCl transfer solution (Church and Gilbert, 1984). Hybridization was performed with a 2463-nt SspI-HindIII fragment from pAd5.SalB (Bernards et al., 1983). This fragment consists 15 of Ad5 bp. 342-2805. The fragment was radiolabeled with  $\alpha$ -<sup>32</sup>P-dCTP with the use of random hexanucleotide primers and Klenow DNA polymerase. The southern blots were exposed to a Kodak XAR-5 film at -80°C and to a Phospho-Imager screen which was analyzed by B&L systems Molecular 20 Dynamics software.

#### A549

Ad5-E1-transformed A549 human bronchial carcinoma 25 cell lines were generated by transfection with pIG.E1A.NEC and selection for G418 resistance. Thirty-one G418 resistant clones were established. Co-transfection of pIG.E1A.E1B with pIG.NEO yielded seven G418 resistant cell lines.

30

#### PER

Ad5-E1-transformed human embryonic retina (HER) cells 35 were generated by transfection of primary HER cells with plasmid pIG.E1A.E1B. Transformed cell lines were established from well-separated foci. We were able to

establish seven clonal cell lines, which we called PER.C1, PER.C3, PER.C4, PER.C5, PER.C6, PER.C8 and PER.C9.

One of the PER clones, namely PER.C6, has been deposited at the ECACC under number 96022940.

5

**Expression of Ad5 E1A and E1B genes in transformed A549 and PER cells**

10 Expression of the Ad5 E1A and the 55-kDa and 21 kDa E1B proteins in the established A549 and PER cells was studied by means of Western blotting, with the use of monoclonal antibodies (mAb). Mab M73 recognizes the E1A products, whereas Mabs AIC6 and ClG11 are directed against the 55-kDa and 21 kDa E1B proteins, respectively.

15 The antibodies did not recognize proteins in extracts from the parental A549 or the primary HER cells (data not shown). None of the A549 clones that were generated by co-transfection of pIG.NEO and pIG.E1A.E1B expressed detectable levels of E1A or E1B proteins (not shown). Some 20 of the A549 clones that were generated by transfection with pIG.E1A.NEO expressed the Ad5 E1A proteins (Fig. 7), but the levels were much lower than those detected in protein lysates from 293 cells. The steady state E1A levels detected in protein extracts from PER cells were 25 much higher than those detected in extracts from A549-derived cells. All PER cell lines expressed similar levels of E1A proteins (Fig. 7). The expression of the E1B proteins, particularly in the case of E1B 55 kDa, was more variable. Compared to 911 and 293, the majority of the PER 30 clones express high levels of E1B 55 kDa and 21 kDa. The steady state level of E1B 21 kDa was the highest in PER.C3. None of the PER clones lost expression of the Ad5 E1 genes upon serial passage of the cells (not shown). We found that the level of E1 expression in PER cells 35 remained stable for at least 100 population doublings. We decided to characterize the PER clones in more detail.

### Southern analysis of PER clones

To study the arrangement of the Ad5-E1 encoding sequences in the PER clones we performed Southern analyses. Cellular DNA was extracted from all PER clones, and from 293 and 911 cells. The DNA was digested with HindIII, which cuts once in the Ad5 E1 region. Southern hybridization on HindIII-digested DNA, using a radiolabeled Ad5-E1-specific probe revealed the presence of several integrated copies of pIG.E1A.E1B in the genome of the PER clones. Figure 8 shows the distribution pattern of E1 sequences in the high molecular weight DNA of the different PER cell lines. The copies are concentrated in a single band, which suggests that they are integrated as tandem repeats. In the case of PER.C3, C5, C6 and C9 we found additional hybridizing bands of low molecular weight that indicate the presence of truncated copies of pIG.E1A.E1B. The number of copies was determined with the use of a Phospho-Imager. We estimated that PER.C1, C3, C4, C5, C6, C8 and C9 contain 2, 88, 5.4, 5, 5 and 3 copies of the Ad5 E1 coding region, respectively, and that 911 and 293 cells contain 1 and 4 copies of the Ad5 E1 sequences, respectively.

### 25 Transfection efficiency

Recombinant adenovectors are generated by co-transfection of adaptor plasmids and the large ClaI fragment of Ad5 into 293 cells (see patent application EP 95202213). The recombinant virus DNA is formed by homologous recombination between the homologous viral sequences that are present in the plasmid and the adenovirus DNA. The efficacy of this method, as well as that of alternative strategies, is highly dependent on the transfectability of the helper cells. Therefore, we compared the transfection efficiencies of some of the

PER clones with 911 cells, using the E.coli  $\beta$ -galactosidase-encoding lacZ gene as a reporter (Fig. 9).

#### Production of recombinant adenovirus

5

Yields of recombinant adenovirus obtained after inoculation of 293, 911, PER.C3, PER.C5 and PER.C6 with different adenovirus vectors are presented in Table II.

10 The results indicate that the yields obtained on PER cells are at least as high as those obtained on the existing cell lines.

15 In addition, the yields of the novel adenovirus vector IG.Ad.MLP1.TK are similar or higher than the yields obtained for the other viral vectors on all cell lines tested.

#### Generation of new adenovirus vectors (Fig. 10).

20 The used recombinant adenovirus vectors (see patent application on EP 95202213) are deleted for E1 sequences from 459 to nt. 3328.

25 As construct pE1A.E1B contains Ad5 sequences 459 to nt. 3510 there is a sequence overlap of 183 nt. between E1B sequences in the packaging construct pIG.E1A.E1B and recombinant adenoviruses, such as e.g. IG.Ad.MLP.TK. The overlapping sequences were deleted from the new adenovirus vectors. In addition, non-coding sequences derived from lacZ, that are present in the original constructs, were deleted as well. This was achieved (see Fig. 10) by PCR 30 amplification of the SV40 poly(A) sequences from pMLP.TK using primers SV40-1 (introduces a BamHI site) and SV40-2 (introduces a BglII site). In addition, Ad5 sequences present in this construct were amplified from nt 2496 (Ad5, introduces a BglII site) to nt. 2779 (Ad5-2). Both 35 PCR fragments were digested with BglII and were ligated. The ligation product was PCR amplified using primers SV40-1 and Ad5-2. The PCR product obtained was cut with

BamHI and AflII and was ligated into pMLP.TK predigested with the same enzymes. The resulting construct, named pMLPI.TK, contains a deletion in adenovirus El sequences from nt 459 to nt. 3510.

5

#### Packaging system

The combination of the new packaging construct pIG.E1A.E1B and the recombinant adenovirus pMLPI.TK, which do not have any sequence overlap, are presented in Fig. 11. In this figure, also the original situation is presented, where the sequence overlap is indicated.

The absence of overlapping sequences between pIG.E1A.E1B and pMLPI.TK (Fig. 11a) excludes the possibility of homologous recombination between packaging construct and recombinant virus, and is therefore a significant improvement for production of recombinant adenovirus as compared to the original situation.

In Fig. 11b the situation is depicted for pIG.E1A.NEO and IG.Ad.MLPI.TK. pIG.E1A.NEO when transfected into established cells, is expected to be sufficient to support propagation of El-deleted recombinant adenovirus. This combination does not have any sequence overlap, preventing generation of RCA by homologous recombination. In addition, this convenient packaging system allows the propagation of recombinant adenoviruses that are deleted just for E1A sequences and not for E1B sequences. Recombinant adenoviruses expressing E1B in the absence of E1A are attractive, as the E1B protein, in particular E1B 19kD, is able to prevent infected human cells from lysis by Tumor Necrosis Factor (TNF) (Gooding et al., 1991).

#### Generation of recombinant adenovirus derived from pMLPI.TK.

35

Recombinant adenovirus was generated by co-transfection of 293 cells with SalI linearized pMLPI.TK

DNA and ClaI linearized Ad5 wt DNA. The procedure is schematically represented in Fig. 12.

Outline of the strategy to generate packaging  
5 systems for minimal adenovirus vector

Name convention of the plasmids used:

P plasmid  
10 I ITR (Adenovirus Inverted Terminal Repeat)  
C Cytomegalovirus (CMV) Enhancer/Promoter Combination  
L Firefly Luciferase Coding Sequence hac,haw Potential  
hairpin that can be formed after digestion with  
restriction endonuclease Asp718 in its correct and in the.  
15 reverse orientation, respectively (Fig. 15).

Eg. pICLhaw is a plasmid that contains the adenovirus  
ITR followed by the CMV-driven luciferase gene and the  
Asp718 hairpin in the reverse (non-functional)  
20 orientation.

1.1 Demonstration of the competence of a synthetic  
DNA sequence, that is capable of forming a hairpin-  
structure, to serve as a primer for reverse strand  
25 synthesis for the generation of double-stranded DNA  
molecules in cells that contain and express adenovirus  
genes.

Plasmids pICLhac, pICLhaw, pICLI and pICL were generated  
using standard techniques. The schematic representation of  
30 these plasmids is shown in Figs. 16-19.

Plasmid pICL is derived from the following plasmids:  
nt.1 - 457 pMLP10 (Levrero et al., 1991)  
nt.458 - 1218 pCMVβ (Clontech, EMBL Bank No. U02451)  
nt.1219 - 3016 pMLP.luc (IntroGene, unpublished)  
35 nt.3017 - 5620 pBLCAT5 (Stein and Whelan, 1989)

The plasmid has been constructed as follows:

The *tet* gene of plasmid pMLP10 has been inactivated by deletion of the BamHI-SalI fragment, to generate pMLP10ΔSB. Using primer set PCR/MLP1 and PCR/MLP3 a 210 bp fragment containing the Ad5-ITR, flanked by a synthetic SalI restriction site was amplified using pMLP10 DNA as the template. The PCR product was digested with the enzymes EcoRI and SgrAI to generate a 196 bp. fragment.

5 Plasmid pMLP10ΔSB was digested with EcoRI and SgrAI to remove the ITR. This fragment was replaced by the EcoRI-SgrAI-treated PCR fragment to generate pMLP/SAL.

Plasmid pCMV-Luc was digested with PvuII to completion and recirculated to remove the SV40-derived poly-adenylation

10 signal and Ad5 sequences with exception of the Ad5 left-terminus. In the resulting plasmid, pCMV-lucΔAd, the Ad5 ITR was replaced by the Sal-site-flanked ITR from plasmid pMLP/SAL by exchanging the XmnI-SacII fragments.

15 The resulting plasmid, pCMV-lucΔAd/SAL, the Ad5 left terminus and the CMV-driven luciferase gene were isolated as an SalI-SmaI fragment and inserted in the SalI and HpaI digested plasmid pBLCATS, to form plasmid pICL. Plasmid pICL is represented in Fig 19; its sequence is presented

20 in Fig. 20.

25

Plasmid pICL contains the following features:

	nt. 1-457	Ad5 left terminus (Sequence 1-457 of human adenovirus type 5)
30	nt. 458-969	Human cytomegalovirus enhancer and immediate
.	early promoter	(Boshart et al., 1985)(from plasmid pCMVβ, Clontech, Palo Alto, USA)
.	nt. 970-1204	SV40 19S exon and truncated 16/19S intron (from plasmid pCMVβ)
35	nt. 1218-2987	Firefly luciferase gene (from pMLP.luc)

nt. 3018-3131     SV40 tandem poly-adenylation signals from  
late transcript, derived from plasmid  
pBLCAT5;  
nt. 3132-5620     pUC12 backbone (derived from plasmid  
pBLCAT5);  
5                nt. 4337-5191      $\beta$ -lactamase gene (Amp-resistance gene,  
reverse orientation)

Plasmid pICLhac and pICLhaw

10

Plasmids pICLhac and pICLhaw were derived from  
plasmid pICL by digestion of the latter plasmid with the  
restriction enzyme Asp718. The linearized plasmid was  
treated with Calf-Intestine Alkaline Phosphatase to remove  
15                the 5' phosphate groups. The partially complementary  
synthetic single-stranded oligonucleotide Hp/aspl en  
Hp/aspl2 were annealed and phosphorylated on their 5' ends  
using T4-polynucleotide kinase.

The phosphorylated double-stranded oligomers were mixed  
20                with the dephosphorylated pICL fragment and ligated. Clones  
containing a single copy of the synthetic oligonucleotide  
inserted into the plasmid were isolated and characterized  
using restriction enzyme digests. Insertion of the  
oligonucleotide into the Asp718 site will at one junction  
25                recreate an Asp718 recognition site, whereas at the other  
junction the recognition site will be disrupted. The  
orientation and the integrity of the inserted  
oligonucleotide was verified in selected clones by  
sequence analyses. A clone containing the oligonucleotide  
30                in the correct orientation (the Asp718 site close to the  
3205 EcoRI site) was denoted pICLhac. A clone with the  
oligonucleotide in the reverse orientation (the Asp718  
site close to the SV40 derived poly signal) was designated  
pICLhaw. Plasmids pICLhac and pICLhaw are represented in  
35                Figs. 16 and 17.

Plasmid pICLI was created from plasmid pICL by  
insertion of the SalI-SgrAI fragment from pICL, containing

the Ad5-ITR into the Asp718 site of pICL. The 194 bp SalI-SgrAI fragment was isolated from pICL, and the cohesive ends were converted to blunt ends using E.coli DNA polymerase I (Klenow fragment) and dNTP's. The Asp718 cohesive ends were converted to blunt ends by treatment with mungbean nuclease. By ligation clones were generated that contain the ITR in the Asp718 site of plasmid pICL. A clone that contained the ITR fragment in the correct orientation was designated pICLI (Fig. 18).

10 Generation of adenovirus Ad-CMV-hcTK. Recombinant adenovirus was constructed according to the method described in Patent application 95202213. Two components are required to generate a recombinant adenovirus. First, an adaptor-plasmid containing the left terminus of the

15 adenovirus genome containing the ITR and the packaging signal, an expression cassette with the gene of interest, and a portion of the adenovirus genome which can be used for homologous recombination. In addition, adenovirus DNA is needed for recombination with the aforementioned

20 adaptor plasmid. In the case of Ad-CMV-hcTK, the plasmid pCMV.TK was used as a basis. This plasmid contains nt. 1-455 of the adenovirus type 5 genome, nt. 456-1204 derived from pCMV $\beta$  (Clontech, the PstI-StuI fragment that contains the CMV enhancer promoter and the 16S/19S intron

25 from Simian Virus 40), the Herpes Simplex Virus thymidine kinase gene (described in Patent application 95202213), the SV40-derived polyadenylation signal (nt. 2533-2668 of the SV40 sequence), followed by the BglII-ScaI fragment of Ad5 (nt. 3328-6092 of the Ad5 sequence). These fragments

30 are present in a pMLP10-derived (Levrero et al., 1991) backbone. To generate plasmid pAD-CMVhc-TK, plasmid pCMV.TK was digested with ClaI (the unique ClaI-site is located just upstream of the TK open readingframe) and dephosphorylated with Calf-Intestine Alkaline Phosphate.

35 To generate a hairpin-structure, the synthetic oligonucleotides HP/cla2 and HP/cla2 were annealed and phosphorylated on their 5'-OH groups with T4-

polynucleotide kinase and ATP. The double-stranded oligonucleotide was ligated with the linearized vector fragment and used to transform E.coli strain "Sure". Insertion of the oligonucleotide into the ClaI site will disrupt the ClaI recognition sites. In the oligonucleotide contains a new ClaI site near one of its termini. In selected clones, the orientation and the integrity of the inserted oligonucleotide was verified by sequence analyses. A clone containing the oligonucleotide in the correct orientation (the ClaI site at the ITR side) was denoted pAd-CMV-hcTK. This plasmid was co-transfected with ClaI digested wild-type Adenovirus-type5 DNA into 911 cells. A recombinant adenovirus in which the CMV-hcTK expression cassette replaces the El sequences was isolated and propagated using standard procedures.

To study whether the hairpin can be used as a primer for reverse strand synthesis on the displaced strand after replication had started at the ITR, the plasmid pICLhac is introduced into 911 cells (human embryonic retinoblasts transformed with the adenovirus El region). The plasmid pICLhaw serves as a control, which contains the oligonucleotide pair HP/asp 1 and 2 in the reverse orientation but is further completely identical to plasmid pICLhac. Also included in these studies are plasmids pICLI and pICL. In the plasmid pICLI the hairpin is replaced by an adenovirus ITR. Plasmid pICL contains neither a hairpin nor an ITR sequence. These plasmids serve as controls to determine the efficiency of replication by virtue of the terminal-hairpin structure. To provide the viral products other than the El proteins (these are produced by the 911 cells) required for DNA replication the cultures are infected with the virus IG.Ad.MLPI.TK after transfection. Several parameters are being studied to demonstrate proper replication of the transfected DNA molecules. First, DNA extracted from the cell cultures transfected with aforementioned plasmids and infected with IG.Ad.MLPI.TK virus is being analyzed by Southern blotting for the

presence of the expected replication intermediates, as well as for the presence of the duplicated genomes. Furthermore, from the transfected and IG.Ad.MLPI.TK infected cell populations virus is isolated, that is 5 capable to transfer and express a luciferase marker gene into luciferase negative cells.

Plasmid DNA of plasmids pICLhac, pICLhaw, pICLI and pICL have been digested with restriction endonuclease SalI and treated with mungbean nuclease to remove the 4 10 nucleotide single-stranded extension of the resulting DNA fragment. In this manner a natural adenovirus 5'ITR terminus on the DNA fragment is created. Subsequently, both the pICLhac and pICLhaw plasmids were digested with restriction endonuclease Asp718 to generate the terminus 15 capable of forming a hairpin structure. The digested plasmids are introduced into 911 cells, using the standard calcium phosphate co-precipitation technique, four dishes for each plasmid. During the transfection, for each plasmid two of the cultures are infected with the 20 IG.Ad.MLPI.TK virus using 5 infectious IG.Ad.MLPI.TK particles per cell. At twenty-hours post-transfection and forty hours post-transfection one Ad.tk-virus-infected and one uninfected culture are used to isolate small molecular-weight DNA using the procedure devised by Hirt. 25 Aliquots of isolated DNA are used for Southern analysis. After digestion of the samples with restriction endonuclease EcoRI using the luciferase gene as a probe a hybridizing fragment of approx. 2.6kb is detected only in the samples from the adenovirus infected cells transfected 30 with plasmid pICLhac. The size of this fragment is consistent with the anticipated duplication of the luciferase marker gene. This supports the conclusions that the inserted hairpin is capable to serve as a primer for reverse strand synthesis. The hybridizing fragment is 35 absent if the IG.Ad.MLPI.TK virus is omitted, or if the hairpin oligonucleotide has been inserted in the reverse orientation.

The restriction endonuclease DpnI recognizes the tetranucleotide sequence 5'-GATC-3', but cleaves only methylated DNA, (that is, only (plasmid) DNA propagated in, and derived, from E.coli, not DNA that has been replicated in mammalian cells). The restriction endonuclease MboI recognizes the same sequences, but cleaves only unmethylated DNA (viz. DNA propagated in mammalian cells). DNA samples isolated from the transfected cells are incubated with MboI and DpnI and analysed with Southern blots. These results demonstrate that only in the cells transfected with the pICLhac and the pICLI plasmids large DpnI-resistant fragments are present, that are absent in the MboI treated samples. These data demonstrate that only after transfection of plasmids pICLI and pICLhac replication and duplication of the fragments occur.

These data demonstrate that in -adenovirus-infected cells linear DNA fragments that have on one terminus an adenovirus-derived inverted terminal repeat (ITR) and at the other terminus a nucleotide sequence that can anneal to sequences on the same strand, when present in single-stranded form thereby generate a hairpin structure, and will be converted to structures that have inverted terminal repeat sequences on both ends. The resulting DNA molecules will replicate by the same mechanism as the wild type adenovirus genomes.

1.2 Demonstration that the DNA molecules that contain a luciferase marker gene, a single copy of the ITR, the encapsidation signal and a synthetic DNA sequence, that is capable of forming a hairpin structure, are sufficient to generate DNA molecules that can be encapsidated into virions.

To demonstrate that the above DNA molecules containing two copies of the CMV-luc marker gene can be encapsidated into virions, virus is harvested from the remaining two cultures via three cycles of freeze-thaw

crushing and is used to infect murine fibroblasts. Forty-eight hours after infection the infected cells are assayed for luciferase activity. To exclude the possibility that the luciferase activity has been induced by transfer of free DNA, rather than via virus particles, virus stocks are treated with DNaseI to remove DNA contaminants. Furthermore, as an additional control, aliquots of the virus stocks are incubated for 60 minutes at 56°C. The heat treatment will not affect the contaminating DNA, but will 5 inactivate the viruses. Significant luciferase activity is only found in the cells after infection with the virus stocks derived from IG.Ad.MLPI.TK-infected cells transfected with the pICLhc and pICLI plasmids. Neither in 10 the non-infected cells, nor in the infected cells 15 transfected with the pICLhw and pICL significant luciferase activity can be demonstrated. Heat inactivation, but not DNaseI treatment, completely eliminates luciferase expression, demonstrating that adenovirus particles, and not free (contaminating) DNA 20 fragments are responsible for transfer of the luciferase reporter gene.

These results demonstrate that these small viral genomes can be encapsidated into adenovirus particles and suggest that the ITR and the encapsidation signal are 25 sufficient for encapsidation of linear DNA fragments into adenovirus particles. These adenovirus particles can be used for efficient gene transfer. When introduced into cells that contain and express at least part of the adenovirus genes (viz. E1, E2, E4, and L, and VA), 30 recombinant DNA molecules that consist of at least one ITR, at least part of the encapsidation signal as well as a synthetic DNA sequence, that is capable of forming a hairpin structure, have the intrinsic capacity to autonomously generate recombinant genomes which can be 35 encapsidated into virions. Such genomes and vector system can be used for gene transfer.

1.3 Demonstration that DNA molecules which contain nucleotides 3510 - 35953 (viz. 9.7 - 100 map units) of the adenovirus type 5 genome (thus lack the E1 protein-coding regions, the right-hand ITR and the encapsidation sequences) and a terminal DNA sequence that is complementary to a portion of the same strand of the DNA molecule when present in single-stranded form other than the ITR, and as a result is capable of forming a hairpin structure, can replicate in 911 cells.

5 In order to develop a replicating DNA molecule that can provide the adenovirus products required to allow the above mentioned pICLhac vector genome and alike minimal adenovectors to be encapsidated into adenovirus particles by helper cells, the Ad-CMV-hcTK adenoviral vector has been developed. Between the CMV enhancer/promoter region and the thymidine kinase gene the annealed oligonucleotide pair HP/cla 1 and 2 is inserted. The vector Ad-CMV-hcTK can be propagated and produced in 911 cell using standard procedures. This vector is grown and propagated

10 exclusively as a source of DNA used for transfection. DNA of the adenovirus Ad-CMV-hcTK is isolated from virus particles that had been purified using CsCl density-gradient centrifugation by standard techniques. The virus DNA has been digested with restriction endonuclease ClaI.

15 The digested DNA is size-fractionated on an 0.7% agarose gel and the large fragment is isolated and used for further experiments. Cultures of 911 cells are transfected with the large ClaI-fragment of the Ad-CMV-hcTK DNA using the standard calcium phosphate co-precipitation technique.

20 Much like in the previous experiments with plasmid pICLhac, the AD-CMV-hc will replicate starting at the right-hand ITR. Once the 1-strand is displaced, a hairpin can be formed at the left-hand terminus of the fragment. This facilitates the DNA polymerase to elongate the chain

25 towards the right-hand-side. The process will proceed until the displaced strand is completely converted to its double-stranded form. Finally, the right-hand ITR will be

30

35

recreated, and in this location the normal adenovirus replication-initiation and elongation will occur. Note that the polymerase will read through the hairpin, thereby duplicating the molecule. The input DNA molecule of 33250 bp, that had on one side an adenovirus ITR sequence and at the other side a DNA sequence that had the capacity to form a hairpin structure, has now been duplicated, in a way that both ends contain an ITR sequence. The resulting DNA molecule will consist of a palindromic structure of approximately 66500 bp.

This structure can be detected in low-molecular weight DNA extracted from the transfected cells using Southern analysis. The palindromic nature of the DNA fragment can be demonstrated by digestion of the low-molecular weight DNA with suitable restriction endonucleases and Southern blotting with the HSV-TK gene as the probe. This molecule can replicate itself in the transfected cells by virtue of the adenovirus gene products that are present in the cells. In part, the adenovirus genes are expressed from templates that are integrated in the genome of the target cells (viz. the E1 gene products), the other genes reside in the replicating DNA fragment itself. Note however, that this linear DNA fragment cannot be encapsidated into virions. Not only does it lack all the DNA sequences required for encapsidation, but also is its size much too large to be endapsidated.

1.4 Demonstration that DNA molecules which contain nucleotides 3503 - 35953 (viz. 9.7 - 100 map units) of the adenovirus type 5 genome (thus lack the E1 protein-coding regions, the right-hand ITR and the encapsidation sequences) and a terminal DNA sequence that is complementary to a portion the same strand of the DNA molecule other than the ITR, and as a result is capable of forming a hairpin structure, can replicate in 911 cells and can provide the helper functions required to encapsidate the pICLI and pICLhac derived DNA fragments.

The next series of experiments aim to demonstrate that the DNA molecule described in part 1.3 could be used to encapsidate the minimal adenovectors described in part 1.1 and 1.2.

5 In the experiments the large fragment isolated after endonuclease ClaI-digestion of Ad-CMV-hcTK DNA is introduced into 911 cells (conform the experiments described in part 1.3) together with endonuclease SalI, mungbean nuclease, endonuclease Asp718-treated plasmid  
10 pICLhac, or as a control similarly treated plasmid pICLhaw. After 48 hours virus is isolated by freeze-thaw crushing of the transfected cell population. The virus-preparation is treated with DNaseI to remove contaminating free DNA. The virus is used subsequently to infect Rat2  
15 fibroblasts. Forty-eight hours post infection the cells are assayed for luciferase activity. Only in the cells infected with virus isolated from the cells transfected with the pICLhac plasmid, and not with the pICLhaw plasmid, significant luciferase activity can be  
20 demonstrated. Heatinactivation of the virus prior to infection completely abolishes the luciferase activity, indicating that the luciferase gene is transferred by a viral particle. Infection of 911 cell with the virus stock did not result in any cytopathological effects.  
25 demonstrating that the pICLhac is produced without any infectious helper virus that can be propagated on 911 cells. These results demonstrate that the proposed method can be used to produce stocks of minimal-adenoviral vectors, that are completely devoid of infectious helper  
30 viruses that are able to replicate autonomously on adenovirus-transformed human cells or on non-adenovirus transformed human cells.

Besides the system described in this application, another approach for the generation of minimal adenovirus  
35 vectors has been disclosed in WO 94/12649. The method described in WO 94/12649 exploits the function of the protein IX for the packaging of minimal adenovirus vectors

(Pseudo Adenoviral Vectors (PAV) in the terminology of WO 94/12649). PAVs are produced by cloning an expression plasmid with the gene of interest between the left-hand (including the sequences required for encapsidation) and 5 the right-hand adenoviral ITRs. The PAV is propagated in the presence of a helper virus. Encapsidation of the PAV is preferred compared to the helper virus because the helper virus is partially defective for packaging. (Either by virtue of mutations in the packaging signal or by virtue 10 of its size (virus genomes greater than 37.5 kb package inefficiently). In addition, the authors propose that in the absence of the protein IX gene the PAV will be preferentially packaged. However, neither of these mechanisms appear to be sufficiently restrictive to allow 15 packaging of only PAVs/minimal vectors. The mutations proposed in the packaging signal diminish packaging, but do not provide an absolute block as the same packaging-activity is required to propagate the helper virus. Also neither an increase in the size of the helper virus nor 20 the mutation of the protein IX gene will ensure that PAV is packaged exclusively. Thus, the method described in WO 94/12649 is unlikely to be useful for the production of helper-free stocks of minimal adenovirus vectors/PAVs.

## References

- Berk, A. J. (1986): *Ann. Rev. genet.* 20, 45-79.
- Bernards, R., Schrier, P. I., Bos, J.L., and Eb,  
A.J. v. d. (1983): Role of adenovirus types 5 and 12  
early region 1b tumor antigens in oncogenic  
transformation. *Virology* 127, 45-53.
- Bett, A.J., Prevec, L., and Graham, F.L. (1993): Packaging  
Capacity and Stability of Human Adenovirus Type-5  
Vectors. *J Virol* 67, 5911-5921.
- Blaese, M., Blankenstein, T., Brenner, M., Cohen-  
Haquenauer, O., Gansbacher, B., Russell, S.,  
Sorrentino, B., and Velu, T. (1995). Vectors in cancer  
therapy: how will they deliver? *Cancer Gene Ther.* 2,  
15 291-297.
- Boshart, M., Weber, F., Jahn, G., Dorsch-Häler, K.,  
Fleckenstein, B., and Scaffner, W. (1985): A very  
strong enhancer is located upstream of an immediate  
early gene of human Cytomegalovirus. *Cell* 41,  
20 521-530.
- Bout, A., Imler, J.L., Schulz, H., Perricaudet, M.,  
Zurcher, C., Herbrink, P., Valerio, D., and Pavirani,  
A. (1994a): *In vivo* adenovirus-mediated transfer of  
human CFTR cDNA to Rhesus monkey airway epithelium:  
efficacy, toxicity and safety. *Gene Therapy* 1,  
25 385-394.
- Bout, A., Perricaudet, M., Baskin, G., Imler, J. L.,  
Scholte, B.J., Pavirani, A., and Valerio, D. (1994b):  
Lung gene therapy: *in vivo* adenovirus mediated gene  
transfer to rhesus monkey airway epithelium.  
*Human Gene Therapy* 5, 3-10.
- Brody, S.L., and Crystal, R.G. (1994): Adenovirus-mediated  
*in vivo* gene transfer. *Ann N Y Acad Sci* 716, 90-101.
- Brough, D.E., Cleghon, V., and Kiessig, D.F. (1992).  
35 Construction, characterization, and utilization of  
cell lines which inducibly express the adenovirus  
DNA-binding protein. *Virology* 190(2), 624-34.

- Brough, D.E., Rice, S.A., Sell, S., and Klessig, D.F. (1985): Restricted changes in the adenovirus DNA-binding protein that lead to extended host range or temperature-sensitive phenotypes. *J. Virol.* 55, 206-212.
- Daniell, E. (1976): Genome structure of incomplete particles of adenovirus. *J. Virol.* 19, 685-708.
- Elsen, P.J.V. d., Houweling, A., and Eb, A. J.V. d. (1983). Expression of region ElB of human adenoviruses in the absence of region ElA is not sufficient for complete transformation. *Virology* 128, 377-390.
- Engelhardt, J.F., Litzky, L., and Wilson, J.M. (1994a): Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. *Hum. Gene Ther.* 5, 1217-1229.
- Engelhardt, J.F., Simon, R.H., Yang, Y., Zepeda, M., Weber-Pendleton, S., Doranz, B., Grossman, M., and Wilson, J.M. (1993): Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. *Human Gene Therapy* 4, 759-769.
- Engelhardt, J.F., Ye, X., Doranz, B., and Wilson, J.M. (1994b): Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. *Proc Natl Acad Sci U S A* 91, 6196-200.
- Fang, B., Wang, H., Gordon, G., Bellinger, D.A., Read, M.S., Brinkhous, K.M., Woo, S.L.C., and Eisensmith, R.C. (1996). Lack of persistence of El recombinant adenoviral vectors containing a temperature sensitive E2A mutation in immunocompetent mice and hemophilia dogs. *Gene Ther.* 3, 217-222.
- Fallaux, F.J., Kranenburg, O., Cramer, S.J., Houweling, A., Ormondt, H. v., Hoeben, R.C., and Eb, A.J. v.d. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early-region- 1-deleted adenoviral vectors. *Hum. Gene Ther.* 7, 215-222.

- Gooding, L.R., Aquino, L., Duerksen-Hughes, P.J., Day, D., Horton, T.M., Yei, S., and Wold, W.S.M. (1991): The ElB 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytalysis of human cells but not of mouse cells. *J. Virol.* 65, 3083-3094.
- Gräble, M., and Hearing, P. (1990): Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. *J. Virol.* 64, 2047-2056.
- Gräble, M., and Hearing, P. (1992): cis and trans Requirements for the Selective Packaging of Adenovirus Type-5 DNA. *J. Virol.* 66, 723-731.
- Graham, F.L., and van der Eb, A.J. (1973): A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 52, 456-467.
- Granam, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977): Characteristics of a human cell line transformed by DNA from adenovirus type 5. *J. Gen. Virol.* 36, 59-72.
- Haddada, H., Ragot, T., Cordier, L., Duffour, M.T., and Perricaudet, M. (1993): Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. *Hum Gene Ther* 4, 703-11.
- Hay, R.T., Stow, N.D., and McDougall, I.M. (1984): Replication of adenovirus minichromosomes. *J. Mol. Biol.* 174, 493-510.
- Hearing, P., Samulski, R.J., Wishart, W.L., and Shenk, T. (1987): Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. *J. Virol.* 61, 2555-2558.
- Horwitz, M.S. (1990): Adenoviridae and their replication, pp. 1679-1740. In B.N. Fields, and D.M. Knipe (Eds): *Virology*, Raven Press, Ltd, New York.
- Hu, C.H., Xu, F.Y., Wang, K., Pearson, A. N., and Pearson, G. D. (1992): Symmetrical Adenovirus Minichromosomes

- Have Hairpin Replication Intermediates. Gene 110, 145-150.
- Imler, J.L., Chartier, C., Dreyer, D., Dieterle, A., Sainte-Marie, M., Faure, T., Pavirani, A., and Mehtali, M. (1996). Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. *Gene Ther.* 3, 75-84.
- Jochimsen, A.G., Peltenburg, L.T.C., Pas, M.F.W.T., Wit, C.M. d., Bos, J.L., and Eb, A.J. v.d. (1987). *EMBO J.* 6, 3399-3405.
- Klessig, D.F., and Grodzicker, T. (1979): Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells maps in the viral gene encoding the 72K DNA-binding protein. *Cell* 17, 957-966.
- Klessig, D.F., Grodzicker, T., and Cleghon, V. (1984): Construction of human cell lines which contain and express the adenovirus DNA binding protein gene by cotransformation with the HSV-1 tk gene. *Virus Res.* 1, 169-188.
- Kruijer, W., Nicolas, J.C., Schaik, F.M. v., and Sussenbach, J.S. (1983): Structure and function of DNA binding proteins from revertants of adenovirus type 5 mutants with a temperature-sensitive DNA replication. *Virology* 124, 425-433.
- Lechner, R.L., and Kelly Jr., T.J. (1977): The structure of replicating adenovirus 2 DNA molecules. *J. Mol. Biol.* 174, 493-510.
- Leij, L. de, Postmus, P. E., Buys, C.H.C.M., Elema, J.D., Ramaekers, F., Poppema, S., Brouwer, M., Veen, A.Y. v.d., Mesander, G., and The, T.H. (1985): Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. *Cancer Res.* 45, 6024-6033.
- Levrero, M., Barban, V., Manteca, S., Ballay, A., Balsamo, C., Avantaggiati, M.L., Natoli, G., Skellekens, H., Ticilais, P., and Perricaudet, M. (1991): Defective

and nondefective adenovirus vectors for expressing foreign genes *in vitro* and *in vivo*. *Gene* 101, 195-202.

Lochmüller, H., Jani, A., Huard, J., Prescott, S.,

5 Simoneau, M., Massie, B., Karpati, G., and Acsadi, G. (1994): Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants ( $\Delta E1 - \Delta E3$ ) during multiple passages in 293 cells. *Hum. Gene Ther.* 5, 1485-1492.

Matsui T., Murayama M. and Mita T. (1986) Adenovirus 2 peptide IX is expressed only on replicated DNA molecules. *Mol. Cell Biol.* 6, 4149-4154.

Michelson, A.M., Markham, A.F., and Orkin, S.H. (1983):

15 Isolation and DNA sequence of a full-length cDNA clone for human X-chromosome encoded phosphoglycerate kinase. *Proc. Natl. Acad. Sci. USA* 80, 472-476.

Morin, J.E., Lubeck, M.D., Barton, J. E., Conley, A.J., Davis, A.R., and Hung, P.P. (1987): Recombinant adenovirus induces antibody response to hepatitis B virus surface antigens. *Proc. Natl. Acad. Sci. USA* 84, 4626-4630.

Nicolas, J.C., Suarez, F., Levine, A.J., and Girard, M. (1981): Temperature-independent revertants of adenovirus H<sub>5</sub>ts125 and H<sub>5</sub>ts107 mutants in the DNA binding protein: isolation of a new class of host range temperature conditional revertants. *Virology* 108, 521-524.

Ostrove, J.M. (1994): Safety testing programs for gene therapy viral vectors. *Cancer Gene Ther.* 1, 125-131.

Pacini, D.L., Dubovi, E.J., and Clyde, W.A. (1984): *J. Infect. Dis.* 150, 92-97.

Postmus, P.E., Ley, L.d., Veen, A.Y. v.d., Mesander, G., Buys, C.H.C.M., and Elema, J.D. (1988): Two small cell lung cancer cell lines established from rigid bronchoscope biopsies. *Eur. J. Clin. Oncol.* 24, 753-763.

- Rice, S.A., and Klessig, D.F. (1985): Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. *J. Virol.* 56, 767-778.
- 5 Roberts, B.E., Miller, J.S., Kimelman, D., Cepko, C.L., Lemischka, I. R., and Mulligan, R. C. (1985): *J. Virol.* 56, 404-413.
- Shapiro, D.L., Nardone, L.L., Rooney, S.A., Motoyama, E.K., and Munoz, J.L. (1978). Phospholipid biosynthesis and secretion by a cell line (A549) which resembles type II alveolar epithelial cells. *Biochim. Biophys. Acta* 530, 197-207.
- 10 Simon, R. H., Engelhardt, J.F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., and Wilson, J.M. (1993): Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. *Human Gene Therapy* 4, 771-780.
- 15 Singer-Sam, J., Keith, D.H., Tani, K., Simmer, R.L., Shively, L., Lindsay, S., Yoshida, A., and Riggs, A.D. (1984): Sequence of the promoter region of the gene for X-linked 3-phosphoglycerate kinase. *Gene* 32, 409-417.
- 20 Stein, R.W., and Whelan, J. (1989): Insulin gene enhancer activity is inhibited by adenovirus 5 ElA gene products. *Mol Cell Biol* 9, 4531-4.
- 25 Stratford-Perricaudet, L.D., and Perricaudet, M. (1991): Gene transfer into animals: the promise of adenovirus, pp. 51-61. In O. Cohen-Adenauer, and M. Boiron (Eds): *Human Gene Transfer*, John Libbey Eurotext.
- 30 Telling, G.C., Perera, S., Szatkowski, J.M., and Williams, J. (1994): Absence of an essential regulatory influence of the adenovirus ElB 19-kilodalton protein on viral growth and early gene expression in human diploid WI38, HeLa, and A549 cells. *J. Virol.* 68, 541-7.
- 35 Tooze, J. (1981): *DNA Tumor Viruses (revised)*. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

- Vieira, J., and Messing, J. (1987): Production of single stranded plasmid DNA, pp. 3-11: *Methods in Enzymology*, Acad. Press Inc.
- Vincent, A.J.P.E., Esandi, M. d. C., Someren,  
5 G.D. v., Noteboom, J.L., C.J.J. A., Vecht, C.,  
Smitt, P.A.E.S., Bekkum, D.W. v., Valerio, D.,  
Hoogerbrugge, P.M., and Bout, A. (1996a). Treatment  
of Lepto-meningeal metastasis in a rat model using a  
recombinant adenovirus containing the HSV-tk gene.  
10 *J. Neurosurg. in press.*
- Vincent, A.J.P.E., Vogels, R., Someren, G. v.,  
Esandi, M. d. C., Noteboom, J.L., Avezaat, C.J.J.,  
Vecht, C., Bekkum, D.W. v., Valerio, D., Bout, A.,  
and Hoogerbrugge, P.M. (1996b). Herpes Simplex Virus  
15 Thymidine Kinase gene therapy for rat malignant brain  
tumors. *Hum. Gene Ther.* 7, 197-205.
- Wang, K., and Pearson, G.D. (1985): Adenovirus sequences  
required for replication *in vivo*. *Nucl. Acids Res.*  
13, 5173-5187.
- White, E., Denton, A., and Stillman, B. (1988): *J. Virol.*  
20 62, 3445-3454.
- Yang, Y., Li, Q., Ertl, H.C.J., and Wilson, J.M. (1995):  
Cellular and humoral immune responses to viral  
antigens create barriers to lung-directed gene therapy  
25 with recombinant adenoviruses. *J. Virol.* 69,  
2004-2015.
- Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol,  
E., and Wilson, J.M. (1994a): Cellular immunity to  
viral antigens limits El-deleted adenoviruses for gene  
30 therapy. *Proc Natl Acad Sci U S A* 91, 4407-11.
- Yang, Y., Nunes, F. A., Berencsi, K., Gonczol, E.,  
Engelhardt, J.F., and Wilson, J. M. (1994b):  
Inactivation of E2A in recombinant adenoviruses  
improves the prospect for gene therapy in cystic  
35 fibrosis. *Nat Genet* 7, 362-9.

Zantema, A., Fransen, J.A.M., Davis-Olivier, A.,  
Ramaekers, F.C.S., Vooijs, G.P., Deleys, B., and  
Eb, A.J. v.d. (1985). Localization of the E1B proteins  
of adenovirus 5 in transformed cells, as revealed by  
interaction with monoclonal antibodies. *Virology* 142,  
5 44-58.

Table I

Primers used for PCR amplification of DNA fragments used for generation of constructs described in this patent application.

Ea-1	CGTGTAGTGTATTTATAACCG	PCR amplification Ad5 nt459 ->
Ea-2	TGCTCACTGGGTGGAAAGCCA	PCR amplification Ad5 nt960 <-
Ea-3	TACCCGCCGTCTAAATGGC	nt1284-1304 of Ad5 genome
Ea-5	TGGACTTGAGCTGTAAACGC	nt1514-1533 of Ad5 genome
Ep-2	<u>GCCTTCATGGAGGTCAAGATGT</u>	nt1721-1732 of Ad5 introduction of NcoI site
Eb-1	GCTTGAGGCCGAGACATGTC	nt3269-3289 of Ad5 genome
Eb-2	<u>GCCTTCAGCTCAATCTGTATCTT</u>	nt3508-3496 of Ad5 genome introduction of XbaI site
SV40-1	<u>GGGGGATCCGAACTTGTTATTGCAGC</u>	Introduction BamHI site (nt2182-2199 of pMLP.TK) adaption of recombinant adenoviruses
SV40-2	<u>GGGAGATCTAGACATGATAAGATAC</u>	Introduction BglII site (nt2312-2297 of pMLP.TK)
Ad5-1	<u>GGGAGATCTGTACTGAAATGTGTGGGC</u>	Introduction BglII site (nt2496-2514 of pMLP.TK)
Ad5-2	GGAGGGCTGCAGTCTCAAACGGCGT	nt2779-2756 of pMLP.TK
ITR1	<u>GGGGGATCTCAAAATCGTCAGTTCCGT</u>	nt35737-35757 of Ad5 (introduction of BamHI site)
ITR2	<u>GGGTCTAGACATCATCAATAATATAC</u>	nt35935-35919 of Ad5 (introduction of XbaI site)

PCR primers sets to be used to create the SalI and Asp718 sites juxtaposed to the ITR sequences.

PCR/MLP1	GGCGAATTCTCGACATCATCAATAATATACC	(Ad5 nt. 10-18)
PCR/MLP2	GSCGAATTCTGGTACCATCATCAATAATATACC	(Ad5 nt. 10-18)
PCR/MLP3	CTGTGTACACCGGGCGCA	(Ad5 nt. 200-184)

Synthetic oligonucleotide pair used to generate a synthetic hairpin, recreates an Asp718 site at one of the termini if inserted in Asp718 site:

HP/aspl 5'-GTACACTGACCTAGTGCCGCCGGCAAAGCCCCGGCGGCACTAGGTCAAG

HP/asp2 5'-GTACCTGACCTAGTGCCGCCGGGCTTGGCCGGGGCGGCACTAGGTCAAGT

Synthetic oligonucleotide pair used to generate a synthetic hairpin, contains the ClaI recognition site to be used for hairpin formation.

HP/cla1 5'-GTACATTGACCTAGTGCCGCCGGCAAAGCCCCGGCGGCACTAGGTCAATCGAT

HP/cla2 5'-GTACATCGATTGACCTAGTGCCGCCGGGCTTGGCCGGGGCGGCACTAGGTCAAT

**TABLE II**

Cell	Passagenumber	IG.Ad.CMV.lacZ	IG.Ad.CMV.TK	IG.Ad.MLP.TK	d1313	Producer	Mean
293		6.0	5.8	21	34	17.5	
911		8	1.4	34	180	59.5	
PER.C3	17	8	11	41	40	25.8	
PER.C5	15	6	17	36	200	64.7	
PER.C6	36	10	22	58	320	102	

Yields x 10<sup>8</sup> pfu/175 flask.

Table II.

Yields of different recombinant adenoviruses obtained after inoculation of adenovirus E1 packaging cell lines 293, 911, PER.C3, PER.C5 and PER.C6. The yields are the mean of two different experiments.

IG.Ad.CMV.lacZ and IG.Ad.CMV.TK are described in patent application EP 95 20 2213

The construction of IG.Ad.MLP.TK is described in this patent application.

Yields of virus per T180 flask were determined by plaque assay on 911 cells, as described [Vallaux, 1996 #1493]

CLAIMS

1. A recombinant nucleic acid molecule based on or derived from an adenovirus having at least a functional encapsidating signal and at least one functional Inverted Terminal Repeat or a functional fragment or derivative thereof and having no overlapping sequences which allow for homologous recombination leading to replication competent virus in a cell into which it is transferred.
- 5 2. A recombinant nucleic acid molecule according to claim 1 being in a linear form and comprising an Inverted Terminal Repeat at or near both termini.
- 10 3. A recombinant nucleic acid molecule according to claim 1 being in a linear and essentially single stranded form and comprising at the 3' terminus a sequence complementary to an upstream part of the same strand of said nucleic acid molecule, said sequence being capable of base-pairing with said part in a way to be able to function as a start-site for a nucleic acid polymerase.
- 15 4. A recombinant nucleic acid molecule according to claim 3, comprising all adenovirus derived genetic information necessary for replication, except for a functional encapsidation signal.
- 20 5. A recombinant nucleic acid molecule derived from the nucleic acid molecule according to claim 4 resulting from the action of a nucleic acid polymerase on said nucleic acid molecule according to claim 4.
- 25 6. A recombinant nucleic acid molecule according to claim 5 having an Inverted Terminal Repeat at both termini.
- 30 7. A recombinant nucleic acid molecule according to anyone of the foregoing claims comprising a host range mutation.
8. A recombinant nucleic acid molecule according to anyone of the foregoing claims comprising a mutated E2

region rendering at least one of its products temperature sensitive.

9. A recombinant nucleic acid molecule according to anyone of the foregoing claims comprising an E2 region under the control of an inducible promoter.

10. A packaging cell for packaging adenovirus derived nucleic acid molecules, which packaging cell has been provided with one or more recombinant nucleic acid molecules which provide said cell with the ability to express adenoviral gene products derived from at least the ElA region.

11. A packaging cell for packaging adenovirus derived nucleic acid molecules, which packaging cell has been provided with one or more recombinant nucleic acid molecules which provide said cell with the ability to express adenoviral gene products derived from at least both the ElA and the E2A region.

12. A packaging cell according to claim 11, wherein the recombinant nucleic acid molecule encoding the E2A region is under control of an inducible promoter.

13. A packaging cell according to claim 11 or 12, wherein the recombinant nucleic acid molecule encoding the E2A region is mutated so that at least one of its products is temperature sensitive.

14. A cell according to anyone of claims 10-13, which does not have the ability to express ElB products.

15. A cell according to claim 14, wherein the genetic information encoding ElB products is not present.

16. A cell according to claim 10, further comprising the region coding for ElB.

17. A cell according to claim 10, further comprising a marker gene.

18. A cell according to claim 17, whereby the marker gene is under control of the ElB responsive promoter.

19. A packaging cell harbouring nucleotides 80-5788 of the human Adenovirus 5 genome.

20. A packaging cell harbouring nucleotides 459-1713 of the human Adenovirus 5 genome.
21. A packaging cell harbouring nucleotides 459-3510 of the human Adenovirus 5 genome.
- 5 22. A cell according to anyone of claims 10-13, which does not have the ability to express the 21kD E1B product.
23. A cell according to claim 22, wherein the genetic information encoding the 21kD E1B product is not present.
- 10 24. A cell according to anyone of claims 10-23 which is a diploid cell.
25. A cell according to anyone of claims 10-24 which is of non-human origin.
26. A cell according to anyone of claims 10-25 which is of monkey origin.
- 15 27. A cell according to claim 19 as deposited under no. 95062101 at the ECACC.
28. A recombinant nucleic acid molecule according to anyone of claims 1-9 being a DNA molecule.
29. A recombinant nucleic acid molecule based on or 20 derived from an adenovirus, having at least a deletion of nucleotides 459-3510 of the E1 region.
30. A recombinant nucleic acid molecule based on or derived from an adenovirus, having a deletion of nucleotides 459-1713 of the E1 region.
- 25 31. An adenovirus-like particle comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
32. A cell comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
33. A recombinant nucleic acid according to claims 1-3, 30 comprising functional E2A and E2B genes or functional fragments or derivatives thereof under control of an E1A independent promoter.
34. A cell according to claim 26 which comprises a host range mutated E2A region of an adenovirus.
- 35 35. A method for intracellular amplification comprising the steps of providing a cell with a linear DNA fragment to be amplified, which fragment is provided with at least

a functional part or derivative of an Inverted Terminal Repeat at one terminus and providing said cell with functional E2 derived products necessary for replication of said fragment and allowing said fragment to be acted upon by a DNA polymerase.

36. A method according to claim 35 whereby the cell is provided with genetic material encoding both E2A and E2B products.

37. A method according to claim 35 or 36 whereby a hairpin-like structure is provided at the terminus of the DNA fragment opposite the Inverted Terminal Repeat.

1/25




Figure 1

Construction of pBS.PGK.PCR1

2/25





Figure 2

Construction of pIG.E1a.E1b.X


3/25



SUBSTITUTE SHEET (RULE 26)

Fig. 3  
Continued on next page


4/25



SUBSTITUTE SHEET (RULE 26)

Fig. 3  
Construction of plG.E1a.NEO


5/25



SUBSTITUTE SHEET (RULE 26)

Fig. 4  
Construction of pIG.E1a.E1b


6/25



SUBSTITUTE SHEET (RULE 26)

**Fig. 4**  
Construction of pIG.E1a.E1b


7/25



SUBSTITUTE SHEET (RULE 26)

Fig. 5  
Construction of pG.NEO

8/25




SUBSTITUTE SHEET (RULE 26)

Figure 6  
Overview of available adenovirus packaging constructs and assessment of their capacity to transform primary kidney cells

9/25

**Figure 7**


Western blotting analysis of A549 clones transfected with pIG.E1A.NEO and PER clones (HER cells transfected with pIG.E1A.E1B)



10/25

**Figure 8**


Southern blot analyses of 293, 911 and PER cell lines



11/25

**Figure 9**

Transfection efficiency of PER.C3, PER.C5, PER.C6 and 911 cells. Cells were cultured in 6-well plates and transfected ( $n=2$ ) with 5  $\mu$ g pRSV.lacZ by calcium-phosphate co-precipitation. Forty-eight hours later the cells were stained with X-GAL. The mean percentage of blue cells is shown.



12/25





Figure 10.  
Construction of pMLPI.TK from pMLP.TK

SUBSTITUTE SHEET (RULE 26)

13/25


**New recombinant adenoviruses and packaging constructs without sequence overlap**



SUBSTITUTE SHEET (RULE 26)

Figure 11a  
Packaging system based on primary cells


14/25

**New recombinant adenoviruses and packaging constructs without sequence overlap**

SUBSTITUTE SHEET (RULE 26)

Figure 11.b  
Packaging system based on established cell lines: transfection with E1a and selection with G418


15/25



SUBSTITUTE SHEET (RULE 26)

Figure 12

16/25



**Figure 13**  
SUBSTITUTE SHEET (RULE 26)

17/25

### Replication of Adenovirus




Figure 14


18/25



Fig 15. The potential hairpin conformation of a single-stranded DNA molecule that contains the HP/asp sequences used in these studies. Restriction with the restriction endonuclease Asp718I of plasmid pICLha<sub>1</sub>, containing the annealed oligonucleotide pair 5 HP/asp1 en HP/asp2 will yield a linear double-stranded DNA fragment. In cells in which the required adenovirus genes are present, replication can initiate at the terminus that contains the ITR sequence. During the chain elongation, the one of the strands will be displaced. The terminus of the single-stranded 10 displaced- strand molecule can adopt the conformation depicted above. In this conformation the free 3'-terminus can serve as a primer for the cellular and/or adenovirus DNA polymerase, resulting in conversion of the displaced strand in a double-stranded form.


**Figure 15**

19/25




**Figure 16**

20/25




**Figure 17**

21/25



**Figure 18**

22/25



**Figure 19**

23/25

Plasmid pICL is derived from the following plasmids:

nt.1 - 457 pMLP10 (Levrero et al., )  
 nt.458 - 1218 pCMVB (Clontech, EMBL Bank no. U02451)  
 nt.1219 - 3016 pMLP.luc (Introgen, unpublished)  
 nt.3017 - 5620 pBLCAT5 (Stein et al., 1989)

The plasmid has been constructed as follows:

The tet gene of plasmid pMLP10 has been inactivated by deletion of the BamHI-SalI fragment, to generate pMLP10ΔSE. Using primer set PCR/MLP1 and PCR/MLP3 a 210 bp fragment containing the Ad5-ITR, flanked by a synthetic SalI restriction site was amplified using pMLP10 DNA as the template. The PCR product was digested with the enzymes EcoRI and SgrAI to generate a 196 bp. fragment. Plasmid pMLP10ΔSE was digested with EcoRI and SgrAI to remove the ITR. This fragment was replaced by the EcoRI-SgrAI-treated PCR fragment to generate pMLP/SAL.

Plasmid pCMV-Luc was digested with PvuII to completion and recirculated to remove the SV40-derived poly-adenylation signal and Ad5 sequences with exception of the Ad5 left-terminus. In the resulting plasmid, pCMV-lucΔAd, the Ad5 ITR was replaced by the SalI-site-flanked ITR from plasmid pMLP/SAL by exchanging the XbaI-SacII fragments. The resulting plasmid, pCMV-lucΔAd/SAL, the Ad5 left terminus and the CMV-driven luciferase gene were isolated as an SalI-SmaI fragment and inserted in the SalI and HpaI digested plasmid pBLCAT5, to form plasmid pICL. Plasmid pICL is represented in figure 19

Plasmid pICL contains the following features:

nt. 1-457 Ad5 left terminus (Sequence 1-457 of human adenovirus type 5)  
 nt. 458-969 Human cytomegalovirus enhancer and immediate early promoter (Bosthart et al., 1985; from plasmid pCMVB)  
 nt. 970-1204SV40 19S exon and truncated 16/19S intron (from plasmid pCMVB)  
 nt. 1218-2987 Firefly luciferase gene (from pMLP.luc)  
 nt. 3018-3131SV40 tandem poly-adenylation signals from late transcript, derived from plasmid pBLCAT5)  
 nt. 3132-5620 pUC12 backbone (derived from plasmid pBLCAT5)  
 nt. 4337-5191β-lactamase gene (Amp-resistance gene, reverse orientation)

NAME: pICL 5620 BPS DNA CIRCULAR UPDATED 5/01/95

DESCRIPTION: 1 x Ad5-ITR, CMV-luciferase, minimal vector

SEQUENCE: sequence based on the available information;

Constructions verified by restriction enzyme digests;

Sequence of regions derived from amplified DNA verified by sequence analyses

\* \* \* S E Q U E N C E \* \* \*

```

1 CATCATCAAT AATATAACCTT ATTTTGGAATT GAAGCCAAATA TGATAATGAG GGGGTGGAGT
61 TTGTGACCGT CCTGGGGGGG TGGGAACGGG SCGGGTCACG TAGTAGTGCG GGGGAAGTGT
121 GATGTTGCCAA GTGTGGGGGA ACACATGTAAC GGACAGGGATG TGCCAAAAGT GACGTTTTTG
181 GTGTGGGGGG GTGTACACAG GAAGTGACAA TTTCGGGGG TTTCAGGGG GATGTTGTAG
241 TAAATTTGG CGTAACCGAG TAAGATTTGG CCATTTTGCG CGGAAACTG AATAAGAGGA
301 AGTGAATTTT GAATAATTTT GTGTTACTCA TAGGGCTAA TATTTCTCTA GGGGGGGGGG
361 GACTTTGACC GTTTACGGTGG AGACTGCCCC AGGTGTTTTT CTGAGGTGTT TTCCGGGTTT
421 CGGGTCAAAAG TTGGGGTTTTT ATTAAATATAG TCAAGGGCTG CAGGTGTTTA CATAACTTAC
481 GGTAAATGGC CGGGCTGGCT GACCGCCCCAA CGAAGGGGGG CCATTCACGT CAATAATGAC
541 GATGGTTGGC ATAGTAACGC CAATAGGGAC TTTCATTOA CTGCAATGGG TGGAGTATTT
601 ACCGTTAACCT GCGGCACTTGG CAGTACACATG AGTGTATGAT ATGCCGAAGTA CGGGGGCTAT
661 TGACGTCAT GACGGTAAT GGCCTGGCTG GCATTATGCC CAGTACATGA CCTTATGGG
721 CTTTCTTACT TGGCACTACA TCTACGTTT ACTCATGCT ATTACCATGG TGATGGGTTT
781 TTGGCACTAC ATCAAATGGGC GTGGATAGGG STTTGACTCA CGGGGGATTTT CAAGTGTCTCA

```

841 CCCCCATTGAC GTCAATGGGA GTTTGTGTTG GCACCAAAAT CAACGGGACT TTCCAAAATG  
 901 TCGTAACAAC TCCGGCCCAT TGACGCCAAT GGGCGGTAGG CGTGTACGGT GGGAGGTCTA  
 961 TATAAGCAGA GCTCGTTTAG TGAACCGTCG GATCGCCTGG AGACGCCATC CACCGCTGTTT  
 1021 TGACCTCCAT AGAACGACCC GGGACCGATC CAGCCTCCGG ACTCTAGAGG ATCCGGTACT  
 1081 CGAGGAACCTG AAAAACCCAGA AAGTTAACCTG GTAAGTTAG TCTTTTGTC TTTTATITCA  
 1141 GGTCCCCGAT CCGGTGGTGG TGCACATCAA AGAACCTGCTC CTACGTGGAT GTTGCCTTTA  
 1201 CTTCTAGTAT CAAGCTGAA TTCCCTTG TGACATTCTT GAATGTCGCT CGCAGTGACA  
 1261 TTAGCATTCG GGTACTGTTG GTAAAATGGA AGACGCCAA AACATAAAGA AAGGCCCGG  
 1321 GCCATTCTAT CCTCTAGAGG ATGGAACCGC TGGAGAGGAA CTGCATAAGG CTATGAAGAG  
 1381 ATACGGCCG GTCCTYUGAA CAATTGCTT TACAGATGCA CATATCSAGG TGAACATCAC  
 1441 GTACGGGAA TACTTCGAAA TGTCGTTCG GTTGGCAGAA GCTATGAAAC GATATGGGT  
 1501 GAATACAAAT CACAGAATCG TGCTATGAG TGAAAACCTCT TTCAATTCTT TTATGCCGGT  
 1561 GTTGGGGCGG TTATTATGAG GAGTTGCGT TGCGCCCGCG AACGACATT ATAATGAACG  
 1621 TGAATTGCTC AACAGATATGA ACATTCGCA GCCTACCGTA GTGTTTGTG CCAAAAGGG  
 1681 GTTGCAAAAA ATTTCGAACG TGCACAAAAAA ATTACCAATA ATCCAGAAAAA TTATTATCAT  
 1741 GGATTCTAAA ACGGATTACC ACGGATTTCGA GTCGATGTC ACCTTCGTC CATCTCATCT  
 1801 ACCTCCCCTGTTTAATGAAT ACGATTTTGT ACCAGAGTCCTTGATGTCGCAACAAACAT  
 1861 TGCACCTGATA ATGAATTCTCT CGGATCTAC TGGGTTACCT AAGGGTGTGG CCCTTCCGCA  
 1921 TAGAACTGCC TGCCTGAGAT TCTCGCATGC CAGAGATCT ATTTCGCAATCATAAATCAT  
 1981 TCCGGATACCT GCGATTTAA GTGTTGTTCC ATTCCATCAC GGTGTTGGAA TGTGTTACTAC  
 2041 ACTCGGATAT TTGATATGTC GATTTGAGT CGTCTTAATG TATAGATTTG AAGAAGAGCT  
 2101 GTTTTACGA TCCCTTCAGG ATTACAAAT TCAAAGTGCCTTGATGTCGCAACAAACAT  
 2161 TTCATTCTTC GCCAAAGCA CTCTGATTGAA CAAATACGAT TTATCTHATT TACACGAAAT  
 2221 TGCTTCTGGG GGGCACCTC TTTCGAAAGA AGTCGGGGAA CGCTTGCAGAACGCTTC  
 2281 TCTTCCAGGG ATACGACAAG GATATGGGCT CACTGAGACT ACATCAGCTA TTCTGATTAC  
 2341 ACCCGAGGGG GATGATAAAC CGGGCGCGGT CGGTAAAGTT GTTCCATTCTT TIGAAGCGAA  
 2401 GTTGTGGAT CTGGATACCG GGGAAACGCT GGGCGTTAAT CAGAGAGGCG AATTATGCT  
 2461 CAGAGGACCT ATGATTATGT CCCCTTATGT AAACAATCCG GAAGCGACCA ACGCCTTGAT  
 2521 TGACAGGAT CGGATCTAC ATTTCGAGA CATAGCTTAC TGGGACGAAG ACGAACACTT  
 2581 TTTCATAGTT GACCGCTTGA AGTCTTAAT TAAATACAAA GGATATCAGG TGGCCCCCGC  
 2641 TGAATTGAA TCGATATTGT TACAAACCCC CAACATCTTC GACGGGGCGG TGGCAGGTCT  
 2701 TCCCGACGAT GACGCCGGTG AACCTCCCGC CGCCGTTGTT GTTGTGGAGC ACGGAAAGAC  
 2761 GATGACGGAA AAAGAGATCG TGGATTACGT CGCCAGTCGA CTAACAACCG CGAAAAGTT  
 2821 GCGGGGAGGA GTTGTGTTTG TGGACGAAGT ACCGAAAGGT CTTACCGGAA AACTCGACGC  
 2881 AAGAAAATC AGAGAGATCC TCATAAAGGC CAAGAAGGGC GGAAAGTCC AATTGTAAAAA  
 2941 TGTAACTGTA TTCACTGATG ACCAAATCTCT TAGTATTTGT AATGGGGAT CCCCAACTTG  
 3001 TTATTGCAAG CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATT CACAAATAAA  
 3061 GCATTTTCTT CACTGCAATTC TAGTTGTTGTTCTTCCAAAC TGATCAATCTT ATCTTATCAT  
 3121 GTCTGGATCG GATCGATCCC CGGGTACCGA GTCGAATTG GTCATGCTG TCATAGCTGT  
 3181 TTCCCTGTGTG AAATTGTTAT CGCTCACAA TTCCACACAA CATAACGCGG GGAAGCATAA  
 3241 AGTGTAAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAG ATTAATTGGG TTGGCCTCAC  
 3301 TGCCCGCTTT CCAGTCGGGA AACCTGTCGT GCCAGCTGCA TTAATGAATC GGCAACCGCG  
 3361 CGGGGAGGG CGGTTGCGT ATTGGGGCT CTTCCGCTTC CTGCTCACT GACTCGCTGC  
 3421 GCTCGGTCGT TCGCTCGCG CGACCGCTAT CAGCTCACTC AAAGGGCGTA ATACGGTTAT  
 3481 CCACAGAATC AGGGGATAAC CGAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA  
 3541 GGAACCGTAA AAAGGGCGCG TTGCTGGCTT TTTCCTCATAG GCTCCGGCCC CCTGACCGAGC  
 3601 ATCACAAAAA TCGACGCTCA AGTCAGAGGT CGCGAAACCC GACAGGACTA TAAAGATACC  
 3661 AGGCGTTTCC CGCTTGGAAAGC TCCCTCGTGC GCTCTCCCTGT TCCGACCTG CCGCTTACCG  
 3721 GATACCTGTC CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA  
 3781 CGTATCTCAG TTGGGTGTAG GTCTGGCTGT CCAAGCTGGG CTGTGTGCAAC GAACCCCCCG  
 3841 TTCACTGGCGA CGCTGCGCC TTATCGGTAA ACTATGCTT TGAGTCCAAC CGCGTAAGAC  
 3901 AGCCTTATC CGCACTGCGA CGACCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG  
 3961 CGCGGTGCTAC AGAGTCTTG AAGTGGTGGC CTAACACTACGG CTACACTAGA AGGACAGTAT  
 4021 TTGGTATCTG CGCTCTGCTG AGGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT  
 4081 CGCCCAAACA AACCAACCGCT GGTAGGGGTG TTGTTTGTG TTGCAAGCAG CAGATTACGC  
 4141 GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACCGCTCACT  
 4201 GGAACGAAAAA CTACGTTAA GGGATTTGG TCATGAGATT ATCAAAAGG ATCTTCACCT  
 4261 AGATCCTTTT AAATTAAAAA TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAAACCTT  
 4321 GGTCTGACAG TTACCAATGC TTAAATGAGTG AGGCACCTAT CTGAGCGATC TGTCTATTTG  
 4381 GTTCACTCCAT AGTTGGCTGA CTCCCCGGTG TGTAGATAAC TACGATAACGG GACGGGCTTAC  
 4441 CATCTGGCGC CAGTGTGCGA ATGATACCGC GAGACCCACG CTCAACCGGCT CGAGATTAT  
 4501 CAGCAATAAA CCAGCCAGCC GGAAGGGCGS AGGGCAGAAG TGGTCTGCA ACTTTATCCG  
 4561 CCTCCATCCA CTCTATTAAAT TGTGCCCCGG AAGCTAGACT AAGTACTTGC CGAGTTAATAA

25/25

4621	GTTTGGCGAA	CGTTGTTGCC	ATTGCTACAG	GCATCGTGGT	GTCACGGCTCG	TGTTTGGTA
4681	TGGCTTCATT	CAGCTCCGGT	TCCCAACGAT	CAAGGGCAGT	TACATGATCC	CCCATGTTGT
4741	GCAAAAAGC	GGTTAGCTCC	TTCCGGTCTC	CGATCGTTGT	CAGAAGTAAG	TTGGCCGCAG
4801	TGTTATCACT	CATGGTTATG	GCAGGACTGC	ATAATTCTCT	TACTGTCATG	CCATCCGTAA
4861	GATGCTTTC	TGTGACTGGT	GAGTACTCAA	CCAAGTCATT	CTGAGAATAG	TGTATGCGGC
4921	GAACCGAGTTG	CTCTTGCCCC	GGCTCAATAC	GGGATAATAC	CGGCCACAT	AGCAGAACTT
4981	TAAAAAGTGT	CATCATTTGGA	AAACCTTCTT	CGGGCGAAA	ACTCTCAAGG	ATCTTACCGC
5041	TGTTGAGATC	CAGTTGATG	TAACCCACTC	GTGCACCCAA	CTGATCTTCA	GCATCTTTA
5101	CTTTCACCAAG	CGTTTCTGGG	TGAGCAAAAA	CAGGAAGGCA	AAATGCCCA	AAAAAGGGAA
5161	TAAGGGCGAC	ACGGAAATGT	TGAATACTCA	TACTCTTCCT	TTTCAATAT	TATTGAAGCA
5221	TTTATCAGGG	TTATTGCTC	ATGAGCGGAT	ACATATTGTA	ATGTATTAG	AAAAATAAAC
5281	AAATAGGGGT	TCCGCGCACA	TTTCCCCGAA	AAGTGCCACC	TGACGTCTAA	AAAACCTTA
5341	TTATCATGAC	ATTAACCTAT	AAAAATAGGC	GTATCACGAG	GCCTATGCGG	TGTGAAATAC
5401	CCGACAGATG	CGTAAGGAGA	AAATACCGCA	TCAGGGGCCA	TTCGCCATTG	AGGCTGCCA
5461	ACTGTTGGGA	AGGGCGATCG	GTGCGGGCCT	CTTCGCTATT	ACGCCAGCTG	GCGAAAGGGG
5521	GATGTGCTGC	AAGGGGATTA	AGTTGGGTA	CGCCAGGGTT	TTCCCAGTCA	CGACGTTGTA
5581	AAACGACGGC	CAGTGCCAAG	CTTGCATGCC	TGCAGGTCGA		

## INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/NL 96/00244

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/86 C12N5/10 //A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 28152 (TRANSGENE S.A.) 8 December 1994 see page 9, last paragraph ---	1-6, 28-33
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, WASHINGTON US, pages 6196-6200, XP002012303 ENGELHARDT ET AL.: "Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver" cited in the application see page 6200, right-hand column ---	8,35-37
X	WO,A,95 02697 (RHONE-POULENC RORER) 26 January 1995 see example 4 ---	9-12, 14-24
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

- \*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&' document member of the same patent family

1	Date of the actual completion of the international search  2 September 1996	Date of mailing of the international search report  06.09.96
	Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl. Fax (+ 31-70) 340-3016	Authorized officer  Cupido, M

## INTERNATIONAL SEARCH REPORT

Int'l Application No.  
PCT/NL 96/00244

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,95 34671 (GENVEC INC.) 21 December 1995  see figure 1 --- WO,A,95 27071 (BOARDS OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 12 October 1995  see page 7, line 9 - page 16; claims 1-27; examples 3-7 --- JOURNAL OF VIROLOGY, vol. 55, pages 206-212, XP002012304 BROUGH ET AL.: "Restricted changes in the adenovirus DNA-binding protein that lead to extended host range or temperature-sensitive phenotypes" cited in the application see the whole document -----	1-6, 9-12, 14-24, 28-33, 35-37  1-3, 9-12, 16-24, 28-33, 35-37  7,25,26, 34
A		

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/NL 96/00244

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9428152	08-12-94	FR-A-	2705686	02-12-94
		AU-B-	6850394	20-12-94
		CA-A-	2141212	08-12-94
		EP-A-	0652968	17-05-95
		JP-T-	7509616	26-10-95
-----	-----	-----	-----	-----
WO-A-9502697	26-01-95	FR-A-	2707664	20-01-95
		FR-A-	2718749	20-10-95
		AU-B-	7264694	13-02-95
		CA-A-	2144040	26-01-95
		CN-A-	1113390	13-12-95
		CZ-A-	9500639	15-11-95
		EP-A-	0667912	23-08-95
		FI-A-	951138	13-04-95
		HU-A-	72558	28-05-96
		JP-T-	8501703	27-02-96
		NO-A-	950939	10-03-95
		NZ-A-	269156	26-03-96
		PL-A-	308122	24-07-95
		ZA-A-	9405012	20-02-95
-----	-----	-----	-----	-----
WO-A-9534671	21-12-95	AU-B-	2770495	05-01-96
-----	-----	-----	-----	-----
WO-A-9527071	12-10-95	AU-B-	2238695	23-10-95
-----	-----	-----	-----	-----